true FY 0001572565 P0Y 0001572565 2023-01-01 2023-12-31 0001572565 2023-12-31 0001572565 2024-06-28 0001572565 2022-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2023-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2022-12-31 0001572565 2022-01-01 2022-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001572565 us-gaap:CommonStockMember 2021-12-31 0001572565 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001572565 INQD:StockPayableMember 2021-12-31 0001572565 us-gaap:RetainedEarningsMember 2021-12-31 0001572565 2021-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001572565 us-gaap:CommonStockMember 2022-12-31 0001572565 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001572565 INQD:StockPayableMember 2022-12-31 0001572565 us-gaap:RetainedEarningsMember 2022-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001572565 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001572565 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001572565 INQD:StockPayableMember 2022-01-01 2022-12-31 0001572565 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001572565 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001572565 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001572565 INQD:StockPayableMember 2023-01-01 2023-12-31 0001572565 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001572565 us-gaap:CommonStockMember 2023-12-31 0001572565 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001572565 INQD:StockPayableMember 2023-12-31 0001572565 us-gaap:RetainedEarningsMember 2023-12-31 0001572565 INQD:AlamoCBDLLCMember us-gaap:CommonStockMember 2017-08-04 2017-08-04 0001572565 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001572565 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001572565 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-12-31 0001572565 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-12-31 0001572565 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001572565 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001572565 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001572565 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001572565 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001572565 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001572565 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001572565 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001572565 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001572565 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001572565 INQD:BoardOfDirectorsMember 2023-04-12 2023-04-12 0001572565 INQD:BoardOfDirectorsMember 2023-04-12 0001572565 us-gaap:WarrantMember 2023-04-12 0001572565 2023-04-12 0001572565 INQD:ElectrumPartnersLLCMember 2023-01-01 2023-12-31 0001572565 INQD:HempThreeSixtyNineMember 2023-01-01 2023-12-31 0001572565 INQD:MetaBioGenixMember 2023-01-01 2023-12-31 0001572565 2020-05-11 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2020-05-11 0001572565 INQD:PromissoryNoteMember INQD:ElectrumPartnersLLCMember 2021-10-01 2021-10-01 0001572565 us-gaap:RestrictedStockMember INQD:ElectrumPartnersLLCMember 2020-09-28 2020-09-28 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2021-11-08 0001572565 INQD:SupplementalAgreementMember INQD:SeriesAConvertiblePreferredStockMember 2021-11-08 2021-11-08 0001572565 INQD:AccreditedInvestorsMember us-gaap:CommonStockMember 2021-11-08 2021-11-08 0001572565 INQD:AccreditedInvestorsMember us-gaap:CommonStockMember 2021-11-08 0001572565 INQD:TenPercentageFixedConvertiblePromissoryNoteMember 2023-11-09 2023-11-09 0001572565 INQD:TenPercentageFixedConvertiblePromissoryNoteMember 2022-08-09 2022-08-09 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2021-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001572565 INQD:SeriesAConvertiblePreferredStockMember 2020-12-31 0001572565 2021-08-27 2021-08-27 0001572565 us-gaap:SeriesAPreferredStockMember 2021-08-27 2021-08-27 0001572565 2021-11-08 2021-11-08 0001572565 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001572565 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001572565 us-gaap:DerivativeMember 2021-01-01 2021-12-31 0001572565 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001572565 srt:MinimumMember us-gaap:PrivatePlacementMember 2022-12-31 0001572565 srt:MaximumMember us-gaap:PrivatePlacementMember 2022-12-31 0001572565 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001572565 us-gaap:PrivatePlacementMember 2023-12-31 0001572565 srt:MinimumMember us-gaap:PrivatePlacementMember 2023-12-31 0001572565 srt:MaximumMember us-gaap:PrivatePlacementMember 2023-12-31 0001572565 INQD:ConsultingServicesMember 2023-01-01 2023-12-31 0001572565 us-gaap:PrivatePlacementMember 2022-02-16 2022-02-16 0001572565 us-gaap:PrivatePlacementMember 2022-03-16 2022-03-16 0001572565 us-gaap:PrivatePlacementMember 2022-02-16 0001572565 us-gaap:PrivatePlacementMember 2022-03-16 0001572565 us-gaap:PrivatePlacementMember INQD:SubscriptionAgreementsMember INQD:AccreditedInvestorsMember 2022-05-12 0001572565 us-gaap:PrivatePlacementMember 2022-08-01 2022-08-01 0001572565 us-gaap:PrivatePlacementMember 2022-08-01 0001572565 us-gaap:PrivatePlacementMember 2022-08-12 2022-08-12 0001572565 us-gaap:PrivatePlacementMember 2022-11-09 2022-11-09 0001572565 us-gaap:PrivatePlacementMember 2022-08-12 0001572565 us-gaap:PrivatePlacementMember 2022-11-09 0001572565 2023-02-01 2023-02-28 0001572565 2021-08-04 2021-08-04 0001572565 INQD:LeslieBocskorMember 2021-08-04 2021-08-04 0001572565 INQD:BenjaminRoteMember 2021-08-04 2021-08-04 0001572565 INQD:DennisForchicMember 2021-08-04 2021-08-04 0001572565 INQD:LeslieBocskorMember INQD:OneYearAnniversaryMember 2021-08-04 2021-08-04 0001572565 INQD:BenjaminRoteMember INQD:OneYearAnniversaryMember 2021-08-04 2021-08-04 0001572565 INQD:DennisForchicMember INQD:OneYearAnniversaryMember 2021-08-04 2021-08-04 0001572565 INQD:RickGutshallMember 2021-08-04 2021-08-04 0001572565 INQD:RickGutshallMember 2021-08-04 0001572565 INQD:LangColemanMember 2021-08-04 2021-08-04 0001572565 INQD:LangColemanMember 2021-08-04 0001572565 INQD:MichaelBlicharskiMember 2022-01-01 2022-12-31 0001572565 INQD:KeithCrouchAndMichaelBlicharskiMember 2022-01-01 2022-12-31 0001572565 INQD:KeithCrouchAndMichaelBlicharskiMember 2022-12-31 0001572565 INQD:AdvisorsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001572565 INQD:AdvisorsMember us-gaap:CommonStockMember 2023-12-31 0001572565 2021-01-01 2021-12-31 0001572565 INQD:ConsultingAgreementMember srt:MaximumMember 2022-12-20 0001572565 INQD:ConsultingAgreementMember 2022-12-20 0001572565 INQD:ConsultingAgreementMember 2022-12-20 2022-12-20 0001572565 2022-02-16 0001572565 us-gaap:WarrantMember 2022-02-16 2022-02-16 0001572565 2022-08-12 0001572565 us-gaap:WarrantMember 2022-08-12 2022-08-12 0001572565 INQD:InvestorWarrantMember 2023-12-31 0001572565 srt:MinimumMember 2023-01-01 2023-12-31 0001572565 srt:MaximumMember 2023-01-01 2023-12-31 0001572565 srt:MinimumMember 2022-01-01 2022-12-31 0001572565 srt:MaximumMember 2022-01-01 2022-12-31 0001572565 2020-12-31 0001572565 2020-01-01 2020-12-31 0001572565 us-gaap:WarrantMember 2021-12-31 0001572565 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001572565 us-gaap:WarrantMember 2022-12-31 0001572565 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001572565 us-gaap:WarrantMember 2023-12-31 0001572565 INQD:AdvisoryAgreementMember INQD:PacificCapitalMarketsLlcMember us-gaap:SubsequentEventMember 2024-02-27 2024-02-27 0001572565 INQD:AdvisoryAgreementMember us-gaap:SubsequentEventMember 2024-06-19 2024-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure INQD:Days

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K/A

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission file number: 000-55594

 

INDOOR HARVEST CORP

(Exact name of registrant as specified in its charter)

 

Texas   45-5577364

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

7401 W. Slaughter Lane #5078

Austin, Texas

  78739
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code:

512-309-1776

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.001 per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
       
Non-accelerated filer Smaller reporting company
       
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☐ No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on December 31st 2023 was $3,105,704, based upon the closing price of $ 0.001 of the registrant’s common stock on that date as reported on OTC Markets Group Inc.

 

As of June 28, 2024, there were 3,205,704,056 shares issued and outstanding.

 

 

 

 
 

 

Explanatory Note

 

This Amendment NO. 2 to our Annual Report on Form-10K for the year ended December 31, 2023, amends in its entirety the Annual Report on Form 10-K that was originally filed on July 1st, 2024 (the “Annual Report”), to:

 

  comply with (17 CFR 240), WHICH REQUIRES ANNUAL FINANCIAL STATEMENTS included in annual reports on Form 10-K to be reviewed by an independent public accountant using professional standards and procedures for conducting such reviews, as established by PCAOB,
     
  to update financial statements and various other disclosures throughout this quarterly report,
     
  to include the required certifications of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act, and,
     
  to include exhibit 101, for XBRL (eXtensible Business Reporting Language) files.

 

This Amendment No. 1 revises the original filing of the Original Report and does not otherwise reflect events that may have occurred subsequent to the original filing date.

 

 

 

 

TABLE OF CONTENTS

 

    PAGE
PART I    
     
Item 1. Business 4
Item 1A. Risk Factors 9
Item 1B. Unresolved Staff Comments 9
Item 2. Properties 9
Item 3. Legal Proceedings 9
Item 4. Mine Safety Disclosures 9
     
PART II    
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 9
Item 6. Selected Financial Data 12
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 15
Item 8. Financial Statements and Supplementary Data 15
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 15
Item 9A. Controls and Procedures 16
Item 9B. Other Information 17
     
PART III    
     
Item 10. Directors, Executive Officers and Corporate Governance 17
Item 11. Executive Compensation 20
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 22
Item 13. Certain Relationships and Related Transactions, and Director Independence 23
Item 14. Principal Accounting Fees and Services 26
     
PART IV    
     
Item 15. Exhibits 27
     
Signatures 29

 

2
 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS AND INFORMATION

 

This Annual Report on Form 10-K, the other reports, statements, and information that we have previously filed or that we may subsequently file with the Securities and Exchange Commission, or SEC, and public announcements that we have previously made or may subsequently make include, may include, incorporate by reference or may incorporate by reference certain statements that may be deemed to be “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to enjoy the benefits of that act. Unless the context is otherwise, the forward-looking statements included or incorporated by reference in this Form 10-K and those reports, statements, information and announcements address activities, events or developments that Indoor Harvest, Corp. (hereinafter referred to as “we,” “us,” “our,” “our Company” or “Indoor Harvest”) expects or anticipates, will or may occur in the future. Any statements in this document about expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “will continue,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” and similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this document. All forward-looking statements concerning economic conditions, rates of growth, rates of income or values as may be included in this document are based on information available to us on the dates noted, and we assume no obligation to update any such forward-looking statements. It is important to note that our actual results may differ materially from those in such forward-looking statements due to fluctuations in interest rates, inflation, government regulations, economic conditions and competitive product and pricing pressures in the geographic and business areas in which we conduct operations, including our plans, objectives, expectations and intentions and other factors discussed elsewhere in this Report.

 

Certain risk factors could materially and adversely affect our business, financial conditions and results of operations and cause actual results or outcomes to differ materially from those expressed in any forward-looking statements speaks only as of the date on which it is made and we do not undertake any obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. The risks and uncertainties we currently face are not the only ones we face. New factors emerge from time to time, and it is not possible for us to predict which will arise. There may be additional risks not presently known to us or that we currently believe are immaterial to our business. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. If any such risks occur, our business, operating results, liquidity and financial condition could be materially affected in an adverse manner. Under such circumstances, you may lose all or part of your investment.

 

The industry and market data contained in this report are based either on our management’s own estimates or, where indicated, independent industry publications, reports by governmental agencies or market research firms or other published independent sources and, in each case, are believed by our management to be reasonable estimates. However, industry and market data is subject to change and cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market shares. We have not independently verified market and industry data from third-party sources. In addition, consumption patterns and customer preferences can and do change. As a result, you should be aware that market share, ranking and other similar data set forth herein, and estimates and beliefs based on such data, may not be verifiable or reliable.

 

3
 

 

PART I

 

Item 1. Business.

 

Organization

 

Indoor Harvest Corp (the “Company”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739 for the year ended 2019. From inception until about August 4, 2017, in summary, the Company pursued a business of certain engineering, procurement and construction related services as to the indoor and vertical farming industry and production platforms, mechanical systems and custom designed build outs for both Controlled Environment Agriculture (“CEA”) and Building Integrated Agriculture (“BIA”), for two unique industries, produce and cannabis.

 

In mid-2016, the Company began efforts to separate its produce and cannabis related pursuits due to ongoing feedback from both clients and potential institutional investors. It was determined that the Company’s involvement in the cannabis industry was creating conflicts for clients and potential institutional investors wishing to work with the Company from the produce industry due to the public perception and political issues surrounding the cannabis industry. By late-2016, the Company had decided to cease actively selling its products and services to the vertical farming industry and to focus on utilizing the Company’s developed technology and methods for the cannabis industry.

 

On August 3, 2017, we formed Alamo Acquisition, LLC, a wholly owned Texas limited liability company (“Alamo Acquisition Sub”). On August 4, 2017, the Company ceased actively supporting business development of vertical farms for produce production and consummated a business acquisition (the “Alamo Acquisition”) pursuant to which Alamo Acquisition Sub acquired all of the outstanding membership interests of Alamo CBD, LLC (“Alamo CBD”), a Texas limited liability company. Upon closing of the Alamo Acquisition, the membership interests of Alamo CBD were exchanged for 7,584,008 shares of Indoor Harvest’s common stock, the parent company of Alamo Acquisition Sub. Alamo CBD continued as our surviving wholly-owned subsidiary, and Alamo Acquisition Sub ceased to exist.

 

On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis.

 

Description of Business

 

Indoor Harvest, through its brand name Indoor Harvest®, was focused on leveraging technology and planning on Vertical Farming, Building Integrated Agriculture, Controlled Environment Agriculture and Aeroponic Cultivation technology with other synergistic enterprises in the Cannabis industry prior to 2020.

 

The 2022 business strategy is to position the Company as an integrated consolidation platform for plant-based industry companies focused on hemp, other hemp-related products, CBD, and other plant-based companies with the potential to be part of a bigger opportunity while sharing intellectual capital, technology, expanded business networks, along with access to new capital markets and liquidity for investors.

 

Our operational expenditures will be focused on our plans to create shareholder value through an M&A and strategic partnership strategy, while managing the necessary costs related to being a fully reporting company with the SEC.

 

4
 

 

Industry and Regulatory Overview

 

The United States federal government regulates drugs through the CSA (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug, which is viewed as highly addictive and having no medical value. The United States Federal Drug Administration (“FDA”) has not approved the sale of cannabis for any medical application. Doctors may not prescribe cannabis for medical use under federal law, however, they can recommend its use under the First Amendment. In 2010, the United States Veterans Affairs Department clarified that veterans using medicinal cannabis will not be denied services or other medications that are denied to those using illegal drugs.

 

State legalization efforts conflict with the CSA, which makes cannabis use and possession illegal on a national level. On August 29, 2013, the U.S. Department of Justice (“DOJ”) issued a memorandum (the “Cole Memo”) providing that where states and local governments enact laws authorizing cannabis-related use, and implement strong and effective regulatory and enforcement systems, the federal government will rely upon states and local enforcement agencies to address cannabis activity through the enforcement of their own state and local narcotics laws.

 

On January 4, 2018, the DOJ suspended the Cole Memo and replaced it with a new Memorandum titled with the subject “Marijuana Enforcement” from Attorney General Jeff Sessions which provides that each U.S. Attorney has the discretion to determine which types of cannabis-related cases should be federally prosecuted, thus ending the broad safe harbor provided under the Cole Memo.

 

In November 2018, Attorney General Sessions resigned and left the DOJ. As a nominee, Attorney General William Barr testified before the U.S. Senate and wrote to Congress that, as Attorney General, he would not seek to prosecute cannabis companies that relied on the Cole Memo and are complying with state law.

 

As of April 25, 2019, 34 states, the District of Columbia and Guam allow their citizens to use medical cannabis through de-criminalization. Within this list of jurisdictions, voters in the States of Alaska, California, Colorado, D.C., Maine, Massachusetts, Nevada, Oregon, Vermont, and Washington have legalized cannabis for adult recreational use.

 

The Company continues to follow and monitor the actions and statements of the Trump administration, the DOJ and Congress’ positions on federal law and cannabis policy. As the possession and use of cannabis is illegal under the CSA, we could be deemed to be aiding and abetting illegal activities through the equipment we intend to sell in the U.S. and directly violating federal law if we should begin producing cannabis under State law. Under federal law, and more specifically the CSA, the possession, use, cultivation, and transfer of cannabis is illegal. Our equipment could be used by persons or entities engaged in the business of possession, use, cultivation, and/or transfer of cannabis.

 

As a result, law enforcement authorities, in their attempt to regulate the illegal use of cannabis, could seek to bring an action or actions against us, including, but not limited to, a claim of aiding and abetting another’s criminal activities or directly violating the CSA. The federal aiding and abetting statute provides that anyone who “commits an offense against the United States or aids, abets, counsels, commands, induces or procures its commission, is punishable as a principal” (18 U.S.C. §2(a).) Enforcement of federal law regarding cannabis would likely result in the Company being unable to proceed with our business plans, could expose us to potential criminal liability and could subject our properties to civil forfeiture which could lead to an entire loss of any investment in the Company. Any changes in banking, insurance or other business services may also affect our ability to operate our business.

 

Although the Company, from 2020 and going forward, intends to focus on plant-based opportunities, hemp businesses, and other ancillary industry companies, changes in the regulatory and legal environment could impact banking, financial, and other business services crucial to the operations of the business.

 

Nothing herein is a legal opinion or a complete or up to date statement on laws, regulations, or policies, especially given the shifting legal and regulatory landscape.

 

Changes in Business Operations

 

2023 was a continuation of our 2020 restructuring, reorganizing, and repositioning of the business. The Company believes it is positioned to start executing its business strategy and leveraging the public company to create shareholder value. The recent long-term commitments of the new management team coupled with a robust business network to support our business initiatives have laid the foundation for the future. We will be working on branding and continuing to build our team in 2024, once we have our new plans funded.

 

The current business strategy is to position the Company as an integrated consolidation platform for opportunities based on the management’s relationships and experience.

 

On February 14, 2022, the Company announced a non-binding letter of intent with Electrum Partners, LLC (EP) to acquire certain assets of EP for an aggregate payment at closing and of a purchase price that will be mutually agreed by the parties based on an independent valuation of the purchased assets.

 

On March 1, 2023, the Company announced an Asset Purchase agreement to acquire certain business assets, including the rights to further develop business opportunities in various stages of due diligence

 

5
 

 

Intellectual Property

 

The Company relies on a strategy of a combination of patent law, trademark laws, trade secrets, confidentiality provisions and other contractual provisions to protect our proprietary rights, which are primarily our brand names, product designs and marks. This does not mean these efforts are up to date or fully effective. The following summarizes certain filings. The Company is currently studying the legal aspects of these, including recent and past communications from counsel and the patent office, and makes no promise or representation as to this information which is subject to correction and update.

 

The Company’s primary trademark is “Indoor Harvest.” This trademark was registered (Registration Number 4,795,471) in the United States on August 18, 2015.

 

The Company filed a patent application (Serial Number 14/120,275) with the United States patent office related to an invention titled: “modular aeroponic system and related methods.” The inventor is Chad Sykes, who assigned the patent application to the Company.

 

We will research the status of our filings and restructure or update as needed this year.

 

Plan of Expanded Operations

 

The current business strategy is to position the Company as an integrated consolidation platform for plant-based industry companies focused on hemp, other hemp-related products, CBD, and other plant-based companies with the potential to be part of a bigger opportunity while sharing intellectual capital, technology, expanded business networks, along with access to new capital markets and liquidity for investors.

 

6
 

 

Sales and Marketing

 

We will be working on branding and building our team in 2023, once we have our new plans funded.

 

Competition and Market Position

 

The current business strategy is to position the Company as an integrated consolidation platform for plant-based industry companies focused on hemp, other hemp-related products, CBD, and other plant-based companies with the potential to be part of a bigger opportunity while sharing intellectual capital, technology, expanded business networks, along with access to new capital markets and liquidity for investors. This may be done by asset acquisitions, mergers, joint ventures, or other strategic initiatives.

 

OTC Markets

 

OTC Markets offer small companies almost comparable benefits of the NYSE or Nasdaq markets, a liquid, secondary trading market, visibility, access to capital, a public market valuation and the ability for small companies to build their brand and reputation across the network, at nearly half the cost of an NYSE listing.

 

We are positioning to compete with other plant-based and hemp related science and consumer product companies trading on the OTC Markets.

 

Employees

 

As of December 31, 2023, we have 0 full-time employees and use a variety of advisors and consultants.

 

Governmental Regulation and Certification

 

Except as set forth below, we are not aware of any material governmental regulations or approvals for any of our products or services.

 

7
 

 

As the possession and use of cannabis is illegal under the CSA, we could be deemed to be aiding and abetting illegal activities through the equipment we intend to sell, lease and license in the U.S. to grow cannabis. Additionally, we would be violating federal law should we begin to manufacture and dispense cannabis under the TCUP. Under federal law, and more specifically the CSA, the possession, use, cultivation, and transfer of cannabis is illegal. Our equipment could be used by persons or entities engaged in the business of possession, use, cultivation, and/or transfer of cannabis. As a result, law enforcement authorities, in their attempt to regulate the illegal use of cannabis, could seek to bring an action or actions against us, including, but not limited, to a claim of aiding and abetting another’s criminal activities or directly violating federal law by manufacturing or distributing cannabis. The federal aiding and abetting statute provides that anyone who “commits an offense against the United States or aids, abets, counsels, commands, induces or procures its commission, is punishable as a principal.” However, we do not believe that our plans to license and sell technology as described herein violates federal law and we believe that we would prevail if any such action were brought against us although there can be no assurance of this.

 

Cannabis is a Schedule-I controlled substance and is illegal under federal law. Even in such states that have legalized the use of cannabis, its use remains a violation of federal law. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in our inability to proceed with our business plan, notably with respect to our plans for cannabis cultivation, production and research. In addition, our assets, including real property, cash, equipment and other goods, could be subject to asset forfeiture because cannabis is still illegal at the federal level should we begin to manufacture and distribute cannabis under the TCUP.

 

In February 2017, the Trump administration made announcements that there could be “greater enforcement” of federal laws regarding cannabis. To this end, on January 4, 2018, the DOJ suspended certain Obama era protections set forth previously in the Cole Memo, as such term is defined above, which was replaced with a new Memorandum titled with the subject “Marijuana Enforcement” from Attorney General Jeff Sessions which provides that each U.S. Attorney has the discretion to determine which types of cannabis-related cases should be federally prosecuted, thus ending the broad safe harbor provided under the Cole Memo. Any such enforcement actions could have a material adverse effect on our business and results of operations. In November 2018, Attorney General Sessions resigned and left the DOJ. As a nominee, Attorney General William Barr testified before the U.S. Senate and wrote to Congress that, as Attorney General, he would not seek to prosecute cannabis companies that relied on the Cole Memo and are complying with state law. The Company plans to continue to follow and monitor the actions and statements of the Trump administration, the DOJ and Congress’ positions on federal law and cannabis policy.

 

The regulatory environment on a Federal, State, and Local level remains opaque and ever changing. This aspect of business risk is in flux and our disclosure should not be deemed a legal opinion or interpreted as fully addressing the myriad regulatory challenges inherent in the industry.

 

Emerging Growth Company Status

 

We are an “emerging growth company” as defined in Section 2(a)(19) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We intend to take advantage of all of these exemptions.

 

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards, and delay compliance with new or revised accounting standards until those standards are applicable to private companies. We have elected to take advantage of the benefits of this extended transition period.

 

We could be an emerging growth company until the last day of the first fiscal year following the fifth anniversary of our first common equity offering, although circumstances could cause us to lose that status earlier if our annual revenues exceed $1.0 billion, if we issue more than $1.0 billion in non-convertible debt in any three-year period or if we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act.

 

8
 

 

Additional Information

 

We are a public company and file annual, quarterly and special reports and other information with the SEC. We are not required to, and do not intend to, deliver an annual report to security holders. Our filings are available, at no charge, to the public at http://www.sec.gov. The company’s website is www.indoorharvest.com,

 

ITEM 1A. Risk Factors.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are not required to provide the information under this item.

 

ITEM 1B. Unresolved Staff Comments.

 

Smaller reporting companies are not required to provide the information required by this item.

 

Item 2. Properties.

 

Our Offices

 

Our headquarters are pending.

 

Item 3. Legal Proceedings.

 

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company may be subject to one or more claims or suits but to our best and current knowledge, there are no current suits at this time.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Trading History

 

Our common stock is quoted on the OTC Markets under the symbol “INQD”. As of December 31, 2023, there were 3,105,704,056 outstanding shares of common stock and approximately 103 shareholders of record. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of bank, brokers and other nominees.

 

Dividends

 

We have not paid any cash dividends on our common stock to date. Any future decisions regarding dividends will be made by our Board of Directors. We do not anticipate paying dividends in the foreseeable future but expect to retain earnings to finance the growth of our business. Our Board of Directors has complete discretion on whether to pay dividends. Even if our Board of Directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the Board of Directors may deem relevant.

 

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Texas Statutes, however, prohibit us from declaring dividends where, after giving effect to the distribution of the dividend:

 

  We would not be able to pay our debts as they become due in the usual course of business; or
     
  Our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution, unless otherwise permitted under our articles of incorporation.

 

9
 

 

Securities Authorized for Issuance under Equity Compensation Plans

 

We do not have in effect any compensation plans under which our equity securities are authorized for issuance.

 

Common Stock

 

As of December 31, 2023 and 2022, there were 3,105,704,056 and 2,693,190,084 shares of common stock issued and outstanding.

 

The holders of our common stock have equal ratable rights to dividends from funds legally available if and when declared by our Board of Directors and are entitled to share ratably in all of our assets available for distribution to holders of common stock upon liquidation, dissolution or winding up of our affairs. Our common stock does not provide the right to a preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions or rights. Our common stockholders are entitled to one non-cumulative vote per share on all matters on which stockholders may vote.

 

All shares of common stock now outstanding are fully paid for and non-assessable. We refer you to our certificate of incorporation, bylaws and the applicable statutes of the State of Texas for a more complete description of the rights and liabilities of holders of our securities.

 

Holders of shares of our common stock do not have cumulative voting rights, which means that the holders of more than 50% of the outstanding shares, voting for the election of directors, can elect all of the directors to be elected, if they so choose, and, in that event, the holders of the remaining shares will not be able to elect any of our directors.

 

Holders of Common Stock

 

We have 103 shareholders of record for our common stock, as of December 31, 2023.

 

Preferred Stock

 

The Company has designated 15,000,000 shares of Series A Preferred Stock with a par value of $0.01.

 

The stated value of each issued share of Series A Convertible Preferred Stock shall be deemed to be $1.00, as the same may be equitably adjusted whenever there may occur a stock dividend, stock split, combination, reclassification or similar event affecting the Series A Convertible Preferred Stock. There are no dividends payables on the Series A Convertible Preferred Stock. Each holder of outstanding shares of Series A Convertible Preferred Stock shall be entitled to cast the number of votes for the Series A Convertible Preferred Stock in an amount equal to the number of whole shares of common stock into which the shares of Series A Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter

 

The Series A Preferred Stock also had a “down-round” protection feature provided to the investors if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $1.00 per common share. The conversion price was automatically adjustable down to the price of the instrument being issued. As a result of conversions during the year ended December 31, 2020, the Series A Preferred Stock conversion price was reset to $0.00006 per share.

 

As of December 31, 2020, the 13 preferred shareholders holding 750,000 preferred shares can convert to 12.5 billion shares of common stock, which was significantly more than the outstanding common stock at that time. As of December 31, 2020, there are currently 2,401,396,041 shares outstanding. The Company has increased its authorized shares to 10 billion shares in May of 2020, addressing the potential Company control issue if conversion of all the preferred shares were to occur at the same time.

 

Upon any liquidation, dissolution or winding-up of the Company under Texas law, whether voluntary or involuntary, the holders of the shares of Series A Convertible Preferred Stock shall be paid an amount equal to the aggregate stated value of their shares of Series A Convertible Preferred Stock, before any payment shall be paid to the holders of common stock, or any other stock ranking on liquidation junior to the Series A Convertible Preferred Stock, an amount for each share of Series A Convertible Preferred Stock held by such holder equal to the sum of the Stated Value thereof.

 

As at December 31, 2020, there were 750,000 shares of Series A Convertible Preferred Stock issued and outstanding.

 

On August 27, 2021, Indoor Harvest Corp (the “Company”) completed an initiative when it entered into a Modification Agreement (the “Modification”) in cooperation with the current Series A Preferred shareholders to modify their conversion privileges to align and support current management team initiatives and shareholder interests. The modification agreement provides the Preferred shareholders the ability to convert into common shares at a conversion price at the lower of $0.40 (per the original agreement), or the subsequent per share pricing of a future equity raise greater than Five Hundred Thousand ($500,000) Dollars. This Modification is forecasted to support anti- dilutive measures potentially to the benefit of our shareholders and may allow the Company to proceed with plans relating to funding needs.

 

On November 8, 2021, the Company finalized a Supplemental agreement with the Series A Preferred shareholders to convert their holdings into common shares of the Company at $0.0125 in alignment and support of the current management team’s initiatives with the goal of benefiting shareholders. This agreement was pursued for the benefit of the Company’s common shareholders to mitigate the potential risk of diluting their shareholding in the event that the Company undertakes additional financing transactions to fund the Company’s expansion initiatives.

 

Pursuant to the Preferred Shareholder’s Supplemental Agreement dated November 8, 2021 (the “Supplemental Agreement”) by and between the Company and holders of its Series A Preferred shares, under which holders of the Series A Preferred shares agreed to convert all of the Series A Preferred shares into common shares of the Company effective November 8, 2021, the Company has issued an aggregate of sixty (60) million restricted common shares. The restricted common shares issued are subject to Rule 144 required holding periods.

 

10
 

 

Transfer Agent and Registrar

 

VStock Transfer, LLC at 18 Lafayette Place, Woodmere, New York 11598 is the registrar and transfer agent for our common stock. Their telephone number is (212) 828-8436.

 

Warrants

 

There are 761,003,846 million warrants outstanding as of December 31, 2023.

 

Options

 

There are 1,024 million outstanding options to purchase our securities as of December 31, 2023. These options are held by the current management team, board of directors, and consultants.

 

Recent Sales of Unregistered Securities

 

During the year ended December 31, 2022, we issued shares of our common stock that were not registered under the Securities Act, and were not previously disclosed in a Current Report on Form 8-K or on a Quarterly Reports on Form 10-Q as follows:

 

During the year ended December 31, 2021, the Company issued 174,513,889 shares of common stock as follows:

 

  16,513,889 shares for conversion of debt of $35,875.
     
  60,000,000 shares for conversion of 750,000 Series A Convertible Preferred stock
     
  98,000,000 shares in private placement offerings

 

During the year ended December 31, 2022, the Company issued 117,280,154 shares of common stock as follows:

 

  116,446,154 shares of common stock for the private placements at $0.005 and $0.0065 per share for cash of $600,000.

 

 

834,000 shares for consulting service valued at $5,000.

 

During the year ended December 31, 2023, the Company issued 412,513,972 shares of common stock as follows:

 

412,513,972 shares of common stock for the private placements at $0.0065, $0.005, $0.001, $0.000375 per share for cash of $1,212,911.

 

Private Placement

 

On February 16, 2022 and March 16, 2022, the Company initiated a private placement offering for the sale of up to 150,000,000 shares of the Company’s common stock, at price of $0.006 per share, for total consideration to the Company of $900,000. On May 12, 2022, the issuance price was updated to $0.005 per share.

 

On March 24, 2022, the Company entered into an agreement with F.E.A. Strategies Group, LLC. as advisory assistance on suitable investment strategies to raise growth capital for the Company. The Company agreed to settle 50% of the advisory fee with 834,000 shares of restricted common stock valued at $5,000 for services rendered.

 

On August 1, 2022, the Company initiated a private placement offering for the sale of up to 123,076,923 shares of the Company’s common stock, at price of $0.0065 per share and an equal number of Warrants with an exercise price of $0.013 for total consideration to the Company of $800,000. On August 12, 2022 and November 9, 2022, the number of shares was updated to 153,846,154 (for total consideration to the Company of $1,000,000) and 200,000,000 shares (for total consideration to the Company of $1,300,000) an equal number of Warrants with an exercise price of $0.013, respectively.

 

During the year ended December 31, 2023, in connection with the mentioned private placement offerings, the company received $1,258,911 in cash proceeds. Out of the $1,258,911, there are $45,000 balances of shares to be issued.

 

As of December 31, 2023, and 2022, there were 3,105,704,056 and 2,693,190,084 shares of Common Stock issued and outstanding, respectively.

 

We relied upon Section 4(a)(2) of the Securities Act of 1933, as amended for the above issuances to U.S. citizens or residents. We believe that Section 4(a)(2) of the Securities Act of 1933 was available because:

 

  None of these issuances involved underwriters, underwriting discounts or commissions.
     
  Restrictive legends were and will be placed on all certificates issued as described above.
     
  The distribution did not involve general solicitation or advertising.
     
  The distributions were made only to investors who were sophisticated enough to evaluate the risks of the investment.

 

In connection with the above transactions, although some of the investors may have also been accredited, we provided the following to all investors:

 

  Access to all our books and records.
     
  Access to documents relating to our operations.
     
  The opportunity to obtain any additional information, including information relating to all of our agreements with third parties which were only oral and not written, to the extent we possessed such information, and including all information necessary to verify the accuracy of the information to which the investors were given access.

 

Prospective investors were invited to review at our offices at any reasonable hour, after reasonable advance notice, any materials available to us concerning our business. Prospective Investors were also invited to visit our offices.

 

11
 

 

Item 6. Selected Financial Data.

 

Not required.

 

Item 7. Management’s Discussion and Analysis Of Financial Condition and Results Of Operations.

 

The discussion of our financial condition and results of operations and business and related within this document should be read in conjunction with our financial statements and the related notes, and other financial information included in this filing. Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

Forward-Looking Statements

 

The following discussion of our financial condition and results of operations should be read in conjunction with our audited financial statements and the related notes, and other financial information included in this filing.

 

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national, and local general economic and market conditions; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; change in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; the risk of foreign currency exchange rate; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

 

You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

Overview

 

The current business strategy continues to be to position the Company as an integrated consolidation platform for plant-based industry companies focused on hemp, other hemp-related products, CBD, and other plant-based businesses with the potential to be part of a bigger opportunity while sharing intellectual capital, technology, expanded business networks, along with access to new capital markets and liquidity for investors.

 

The company spent the majority of 2021 reorganizing, restructuring, and repositioning the business. In 2022, those efforts have allowed the company to begin moving forward on its business strategy of developing and acquiring operating businesses, beginning with the letter of intent announced with Electrum Partners, LLC.

 

The Company was funded through a convertible note structure from 2017 into 2019, which allowed the Company to keep being active while we restructure, reposition and recapitalize the company. We continue to seek funding from other capital sources as we position the company for future growth.

 

As part of the restructuring and recapitalization effort, the Company plans to regularly increases the number of shares of common stock the Company is authorized to issue. We believe this will enable the Company to raise additional capital by allowing funding sources to be able to convert debt to shares, a common form of funding, and to utilize shares as currency for future M&A transactions or related strategic initiatives.

 

Raising new capital is critical to the Company going forward and is a primary focus to support the current acquisition and growth strategy.

 

12
 

 

The current business strategy continues to be to position the Company as an integrated consolidation platform for plant-based industry companies focused on hemp, other hemp-related products, CBD, and other plant-based businesses with the potential to be part of a bigger opportunity while sharing intellectual capital, technology, expanded business networks, along with access to new capital markets and liquidity for investors.

 

Our operational expenditures will primarily focus on review of existing assets, vetting potential merger or acquisition targets and related due diligence costs, as well as the necessary costs related to being a fully reporting company with the SEC.

 

On March 5, 2020, The Company entered into a material definitive agreement with Fincann Corp., a New York corporation (the “Fincann”). Fincann provides banking related strategies or solutions for the cannabis-related industry through a growing consortium of financial institutions, to help marijuana-related businesses (MRBs) to access essential banking services without complicated workarounds.

 

On February 14, 2022, the Company entered into a non-binding letter of intent with Electrum Partners, LLC (EP) to acquire certain assets of EP for an aggregate payment at closing and of a purchase price that will be mutually agreed by the parties based on an independent valuation of the purchased assets.

 

On March 1, 2023, the Company announced an Asset Purchase agreement to acquire certain business assets, including intellectual property, goodwill, and the rights to certain business opportunities in various stages of due diligence from EP.

 

On April 12, 2023, the company’s board of directors approved to issue a convertible note of $312,500 with 20% discount, at rate of 6% per annum and maturity date shall be ninety days after issuance of note (April 12, 2023). The Company’s board of directors also deems it in the best interest of the Company to issue to investor 31,250,000 shares of common stock with exercise price of $0.01 per share subject to adjustment and for term of five years. Pursuant to the agreement, the Company obtained $180,500 in cash after distribution attorney and brokers fees.

 

The Company is in the process of establishing a headquarters.

 

We are an “emerging growth company” (“EGC”) that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act (“the JOBS Act”), that eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the SEC’s reporting and disclosure rules. We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Because of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

 

Results of Operations

 

The following summary of our results of operations should be read in conjunction with our consolidated financial statements for the years ended December 31, 2023 and 2022, which are included herein.

 

For the year ended December 31, 2023 compared to the year ended December 31, 2022

 

Our operating results for the years ended December 31, 2023 and 2022 and the changes between those periods for the respective items are summarized as follows:

 

   Years Ended         
   December 31,         
   2023   2022   Change   % 
Revenue  $-   $-   $-    - 
Operating expenses                    
Professional fees   1,566,940    1,567,352    (412)   0%
General and administrative expenses   400,473    1,803,461    (1,402,988)   (78)%
Total operating expenses   1,967,414    3,370,813    (1,403,399)   (42)%
Loss from operations   (1,967,414)   (3,370,813)   1,403,399    (42)%
Other expense                    
Interest income   3,373    7,216    (3,843)   (53)%
Amortization of OID   (312,500)   -    (312,500)   100%
Interest Expense   (360,788)   -    (360,788)   100%
Impairment loss   (624,289)   -    (624,289)   100%
Total other expense   (1,294,204)   7,216    1,301,420    18035%
Net loss  $(3,261,618)  $(3,363,597)  $101,979    (3)%

 

13
 

 

Revenues

 

During the years ended December 31, 2023 and 2022, the Company generated no revenue.

 

Operating Expenses

 

Total operating expenses for the years ended December 31, 2023 and 2022 were $1,967,414 and $3,370,813 respectively, for an aggregate decrease in expenses of $1,403,399 or 42%. The aggregate decrease is primarily related to General and Administrative Expenses.

 

Other Expense

 

Total other expense for the year ended December 31, 2023 and 2022 were $(1,294,204) and $7,216, for an increase of $1,301,420 or 18035%. The increase was primarily related to the amortization of convertible notes discount of $312,500 and impairment loss of $624,289.

 

Net Income

 

As a result of the factors discussed above, net loss for the year ended December 31, 2023 was a loss of $3,261,618 as compared to a net loss of $3,363,597 for the year ended December 31, 2022, which reflects a decrease of $101,979 or 3%.

 

Liquidity and Capital Resources

 

The following table provides selected financial data about our Company as of December 31, 2023 and December 31, 2022, respectively.

 

Working Capital

 

   December 31,   December 31,         
   2023   2022   Change   % 
Current assets  $37,417   $433,904   $(396,487)   (91)%
Current liabilities  $1,327,085   $233,378   $1,093,707    469%
Working capital (deficiency)  $(1,289,667)  $200,526   $(1,490,193)   (743)%

 

Cash Flows

 

   Years Ended         
   December 31,         
   2023   2022   Change   % 
Cash used in operating activities  $(518,942)  $(877,619)  $358,677    (41)%
Cash used in investing activities  $(479,289)  $(305,000)  $(174,289)   57%
Cash provided by financing activities  $772,000   $1,176,000   $(404,000)   (34)%
Net Change in Cash During Period  $(226,231)  $(6,619)  $(219,612)   3318%

 

As of December 31, 2023, our Company’s cash balance was $0 and total assets were $37,417. As of December 31, 2022, our Company’s cash balance was $226,231 and total assets were $578,904. The decrease in total assets was primarily the result of a decrease in financing activities.

 

As of December 31, 2023, our Company had total liabilities of $1,327,085, compared with total liabilities of $233,378 as at December 31, 2022. The increase in total liabilities was primarily related to accrued expense and issuance of convertible notes into fiscal year end.

 

14
 

 

As of December 31, 2023, our Company had a working capital deficiency of $1,289,667 compared with working capital of $200,526 as of December 31, 2022. The increase in working capital deficiency was primarily attributed to a decrease in financing activities and increase in cash used in investing activities.

 

Cash Flow from Operating Activities

 

Net cash used in operating activities for the year ended December 31, 2023 and 2022 were $(518,942) and $(877,619), respectively, for a decrease of $358,677. The decrease in net cash used in operating activities is primarily related to business development activities and operating expenses due to less activities in operations and decreased stock option compensation to advisors and directors.

 

Cash Flow from Investing Activities

 

During the year ended December 31, 2023 and 2022, the Company utilized $(479,289) and $(305,000), respectively, in investing activities.

 

Cash Flow from Financing Activities

 

Net cash provided by financing activities for the year ended December 31, 2023 and 2022 were $772,000 and $1,176,000, respectively, for an decrease of $404,000. During the year December 31, 2023, the Company received $522,000 through private placements stock subscriptions. During the year December 31, 2022, the Company received $1,176,000 through private placements stock subscriptions.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders

 

Critical Accounting Policies and Estimates

 

For a discussion of our accounting policies and related items, please see the Notes to the Financial Statements, included in Item 8.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required.

 

Item 8. Financial Statements and Supplementary Data.

 

The consolidated financial statements and Reports of Independent Registered Public Accounting Firms are listed in the “Index to Consolidated Financial Statements” on page F-1 and included on pages F-2 through F-23.

 

Item 9 – Changes in and Disagreements With Accountants on Accounting and Financial Disclosures.

 

On November 15, 2019, the Company replaced Thayer O’Neal Company with WWC, P.C. as our independent principal accountant to audit the Company’s financial statements.

 

15
 

 

Item 9A – Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

The Company’s Chief Executive Officer (the principal executive officer and principal financial officer) have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023. Based upon such evaluation, Chief Executive Officer (the principal executive officer and principal financial officer) have concluded that, as of December 31, 2023, the Company’s disclosure controls and procedures were not effective.

 

Management’s Report on Internal Control over Financial Reporting

 

Under the supervision and with the participation of our management, including our Chief Executive Officer (the principal executive officer and principal financial officer), we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023, based on the framework stated by the Committee of Sponsoring Organizations of the Treadway Commission’s 2013 Framework.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control system was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes, in accordance with generally accepted accounting principles. Because of inherent limitations, a system of internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to change in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Based on its evaluation as of December 31, 2023, our management concluded that our internal controls over financial reporting were not effective as of December 31, 2023 due to the material weaknesses set forth below. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Because of the Company’s limited resources, there are limited controls over financial information processing. The Company determined that its internal control over financial reporting was not effective as of December 31, 2023. The basis for the conclusions that such internal control was ineffective included the following considerations:

 

  We currently have insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.
     
  Additionally, there is a lack of formal process and timeline for closing the books and records at the end of each reporting period and such weaknesses restrict the Company’s ability to timely gather, analyze and report information relative to the financial statements.
     
  Our Company’s management is composed of a small number of individuals resulting in a situation where limitations on segregation of duties exist.

 

Material risks associated with the above issues include the following:

 

  Because the Company currently has insufficient written policies and procedures with regard to financial reporting, this could cause the Company to be inefficient and potentially encounter errors in preparing its financial reports due to the lack of a written policy for the company to follow.
     
  Because there is a lack of formal process and timeline, this cold lead the Company not to be able to timely prepare its financial statements and could cause it to either file a report late or to a file a report which may contain some errors.
     
  Because the Company’s management is composed of a small number of persons, there is a lack of segregation of duties.

 

This report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. We were not required to have, nor have we, engaged the Company’s independent registered public accounting firm to perform an audit of internal control over financial reporting pursuant to the rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

 

16
 

 

Changes in Internal Controls over Financial Reporting

 

There has been no change in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 under the Exchange Act that occurred during the quarter ended December 31, 2023 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

The following sets forth our Officers and Directors as of December 31, 2023. The Board of Directors elects our Executive Officers annually. Our Directors shall be elected for the term of one year, and until their successors are elected and qualified, or until their earlier resignation or removal. Our Officers also shall be elected for the term of one year, and until a successor is elected and qualified, or until an earlier resignation or removal. Our Directors and Executive Officers are as follows:

 

Name   Position   Age
Leslie Bocskor   Chief Executive and Chief Financial Officer   58
         
Keith Crouch   Director   47
Michael Blicharski   Director   42

 

Effective May 11, 2020, the Company (Registrant) mutually and amicably completed a change of officers, as to the principal accounting officer and principal executive officer, the person serving in the capacity of interim CEO and interim CFO. Mr. Cook, serving as both up to such time, departed, and no longer serves in any officer or Director capacity. The Board of Directors appointed Leslie Bocskor to act as a principal executive officer serving in the capacity of CEO with non-material arrangements to apply moving forward, including compensation of $2,500 monthly, potential stock, and other considerations, indemnifications, and reimbursement of expenses.

 

Effective August 4, 2021, Board of Directors, voted to formalize employment agreements with Messrs. Bocskor and Rote. Mr. Bocskor will continue to serve in the CEO and CFO roles, while Benjamin Rote will fulfill the role of Chief Operating Officer as the Company focuses on executing its acquisitions and business development strategy.

 

17
 

 

Rick Gutshall. Mr. Gutshall served as our Interim Chief Executive Officer from August 2017 to February 20, 2018 and has served as a member of our Board of Directors since August 2017 and served as our Chief Financial Officer from August 2017 to December 2017. Since 2016, Mr. Gutshall has served as Chief Financial Officer of Alamo CBD LLC, and since 1999, he has served as a principal of KW Gutshall & Associates (“KW Gutshall”). Mr. Gutshall is responsible for personalized financial planning, wealth management and retirement planning for clients at KW Gutshall and has been a licensed financial advisor since 1997. Mr. Gutshall received his Bachelor of Business Administration, Management and Operations from Concordia University-Austin in 1997. As a member of the Board, Mr. Gutshall will contribute the benefits of his executive leadership and management experience in finance, business development, contract negotiations and public speaking. On February 20, 2018, Mr. Rick Gutshall resigned as Interim Chief Executive Officer of the Company.

 

Dr. Lang Coleman. In August 2017, Dr. Lang Coleman was appointed as a member of the Board. Dr. Coleman is a proud disabled Army veteran, long-time Texas resident, and psychologist specializing in Neuropsychology. Dr. Coleman received his B.S. and M.A. from Austin Peay State University in Clarksville, Tennessee, his Ph.D. in Clinical Psychology from the University of Kansas, and he attended law school at the University of Texas at Austin. Dr. Coleman completed his medical internship at William Beaumont Army Medical Center in El Paso, Texas, and spent 22 years, from 1972 through 1994, in U.S. Army Psychiatry. A pensioned Army Officer and decorated combat veteran, Dr. Coleman formerly directed soldiers and planned both treatments and evacuations for psychiatric casualties in a theatre of war for over 30,000 soldiers and marines. From his time as an Army Major, he has extensive knowledge and experience with chain of custody in his dealings with deliverables ranging from drug-testing biological samples to weapons and ordinance and holds the Combat Medical Badge. After serving 17 years, from 1998 through 2015, Dr. Coleman retired as a tenured professor of psychology at St. Philip’s College in San Antonio, Texas, where he taught Abnormal Psychology and Statistics courses. Dr. Coleman authored curriculum in 1994 for a juvenile justice alternative education program and licensed the copyright, for one year, to The Key Corporation. The school was successfully launched in Dallas. As the CEO of Alamo CBD since March 2017, Dr. Coleman has regularly facilitated, sponsored and participated in many community activities. He has frequently appeared on television and at the Texas State Capital as an advocate for the Compassionate-Use Program. As a member of the Board, Dr. Coleman will contribute the benefits of his military experience treating veterans with post-traumatic stress disorder, or PTSD, and other medical conditions and will manage the Company’s medical and science policy and procedures. His contributions and deep understanding of all aspects of our business and industry will provide considerable experience in developing the Company’s medical and scientific procedures and policies.

 

Keith Crouch. Keith Crouch is a CPG Sales and Marketing leader with in-depth expertise in branded and private label product launches, currently managing global brand portfolios of over $1.0B across grocery, mass, drug, c-store, and direct to consumer channels. He has owned, operated and worked with many companies, and has been fortunate enough to enjoy a dynamic award winning sales and management career that has included aiding in the successful growth of a variety of well-known firms and brands that include: Health Valley Foods, Cliff Bar, Kraft Foods, Quaker, Nabisco, Kikkoman, Twining’s Tea, Bigelow Tea, Stubbs BBQ, Frontera Foods, Lotus Foods, Sam Mills, Jose Cuervo, and Branded Entertainment, just to name a few. Mr. Crouch’s experience in CPG makes him an asset to the Board of Directors, which he has served since June 21, 2022.

 

Michael Blicharski. Michael Blicharski is a serial entrepreneur and financial services professional who has enjoyed acquiring and growing businesses in a variety of industries over a 15-year career including food and beverage distribution and video game development, with additional experience in non-profit advisory and international trade as both consultant and investor in multiple startups and early-stage companies. He has worked in spaces that are quite complementary to the hemp space and understands the vision for products that go from innovative into mainstream markets., which makes him an asset to the Board of Directors. Mr. Blicharski was appointed to the Board of Directors on June 21, 2022.

 

Leslie Bocskor. Mr. Bocskor has been the Company’s CEO and CFO since his appointment on May 20, 2020. He is also the Chairman and founder of Electrum Partners or “EP.” EP is involved in a variety of related industry ventures and consulting. He is a recognized industry consultant in the legal cannabis area and interacts with mainstream media often being featured, including Forbes, CNBC, The Wall Street Journal, and more. He formed Electrum Partners in 2014 and became the founding Chairman of the Nevada Cannabis Industry Association (NVCIA). He is an active speaker at industry conferences, including the ArcView Group. Leslie began his career at Lehman Brothers and later went on to co-found Mason Cabot, a New York based investment bank focused on emerging technologies and finance. In 2005, he served as Managing Partner with Lennox Hill Partners. Bocskor often advised politicians, industry leaders, and investment firms who seek out his groundbreaking analysis and insight into the cannabis economy.

 

18
 

 

Family Relationships

 

There are no family relationships between any director or executive officer.

 

Involvement in Certain Legal Proceedings

 

No officer, director, or persons nominated for such positions, promoter or significant employee has been involved in the last ten years, to our belief, in any of the following:

 

  Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time,
     
  Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses),
     
  Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities,
     
  Being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.
     
  Having any government agency, administrative agency, or administrative court impose an administrative finding, order, decree, or sanction against them as a result of their involvement in any type of business, securities, or banking activity.
     
  Being the subject of a pending administrative proceeding related to their involvement in any type of business, securities, or banking activity.
     
  Having any administrative proceeding been threatened against you related to their involvement in any type of business, securities, or banking activity.

 

19
 

 

Item 11. Executive Compensation.

 

The was no compensation awarded to, earned by, or paid to each named executive officer for the Company’s last completed fiscal year of 2023 for all services rendered to the Company.

 

Employment Agreements

 

Past Agreements-Daniel Weadock, Chief Executive Officer and Director

 

On February 20, 2018, Mr. Daniel Weadock was appointed Chief Executive Officer and Director of the Company. On February 20, 2018, the Company entered into an executive employment agreement with Mr. Weadock (the “Weadock Employment Agreement”), pursuant to which Mr. Weadock agreed to act as the Company’s chief executive officer. Pursuant to the terms of the Weadock Employment Agreement, Mr. Weadock will initially not receive a salary. However, effective on the business day after the date on which the Company achieves Capitalization of $2,000,000 or more, Mr. Weadock’s annual base salary will be $100,000. For purposes of the Weadock Employment Agreement, “Capitalization” means aggregate net cash proceeds received by the Company from (a) the Company’s sale of common stock pursuant to Puts (as such term is defined in the Investment Agreement dated as of October 12, 2017 by and between the Company and Tangiers Global, LLC (the “Investment Agreement”)) under the Investment Agreement, and/or (b) any other sale by the Company of common stock or preferred stock, whether in a public offering or a private placement. In addition, pursuant to the terms of the Weadock Employment Agreement, the Company agreed to grant Mr. Weadock (i) 300,000 shares of restricted stock as soon as administratively practicable following execution of the Weadock Employment Agreement, and (ii) 1,584,202 shares of restricted common stock, consistent with the grant and vesting schedule set forth in the Weadock Employment Agreement; provided, however, that no grant will be made and no shares will be issued with respect to any grant if Mr. Weadock is not employed by the Company as an executive on the respective Date of Grant as set forth in the Weadock Employment Agreement. The Weadock Employment Agreement has a term of one year, unless Mr. Weadock’s employment is terminated sooner by the board of directors, and the term will be extended for additional one-year periods unless the Company or Mr. Weadock gives the other party at least 30 days’ prior written notice of its intent not to renew.

 

On February 20, 2018, the Company also entered into a compensation agreement with Mr. Weadock (the “Director Compensation Agreement”). Pursuant to the terms of the Director Compensation Agreement, the Company agreed to grant Mr. Weadock an aggregate of 240,000 shares of restricted shares of common stock of the Company, consistent with the grant and vesting schedule set forth in the Director Compensation Agreement; provided, however, that no grant will be made and no shares will be issued with respect to any grant, if Mr. Weadock is not a member of the Company’s board of directors on the respective Date of Grant as set forth in the agreement. If the Company is acquired by, or merged into and with, another entity prior to the last Date of Vesting set forth in the agreement (i.e. February 23, 2022), all shares issuable to Mr. Weadock under the Director Compensation Agreement will become fully vested and non-forfeitable. The Company also agreed to reimburse Mr. Weadock for all reasonable travel and incidental expenses incurred by Mr. Weadock in performing his services and attending meetings as approved in advance by the Company.

 

Additionally, on February 20, 2018, the Company entered into an indemnity agreement with Mr. Weadock (the “Weadock Indemnity Agreement”). Pursuant to the terms of the Weadock Indemnity Agreement, the Company agreed to use reasonable efforts to obtain and maintain in full force and effect directors’ and officers’ liability insurance (“D&O Insurance”) in reasonable amounts from established and reputable insurers; provided, however, the Company shall have no obligation to obtain or maintain D&O Insurance if the Company determines in good faith that such insurance is not reasonably available, the premium costs for such insurance are disproportionate to the amount of coverage provided, the coverage is reduced by exclusions so as to provide an insufficient benefit, or Mr. Weadock is covered by similar insurance maintained by a subsidiary of the Company. In addition the foregoing, the Company will indemnify Mr. Weadock from certain third party actions, derivative actions and actions where Mr. Weadock is decreased; provided, however, the Company shall not be obligated to indemnify Mr. Weadock for actions including, but not limited to, actions initiated by Mr. Weadock, for any action in which it is determined that the material assertions made by Mr. Weadock in such proceeding were not made in good faith or were frivolous, for any settlements not authorized by the Company, for any actions on the account of Mr. Weadock’s willful misconduct, and for any expenses and the payment of profits arising from the purchase and sale Mr. Weadock of securities in violation of Section 16(b) of the Securities Exchange Act, or any similar successor statute; provided, further that, that the Company shall not be obligated to indemnify Mr. Weadock for expenses or liabilities of any type whatsoever which have been paid directly to Mr. Weadock pursuant to the Company’s D&O Insurance policy.

 

Mr. Weadock no longer has an employment agreement.

 

Rick Gutshall, Former Interim Chief Executive Officer and Current Director

 

Mr. Gutshall served as our Interim Chief Executive Officer from August 2017 until February 2018 as a member of our Board of Directors since August 2017, and as our Chief Financial Officer from August 2017 to December 2017. On August 9, 2017, the Company entered into a director agreement (the “Gutshall Director Agreement”), employment agreement (the “Gutshall Employment Agreement”) and an indemnity agreement (the “Gutshall Indemnity Agreement”) with Rick Gutshall. The Gutshall Employment Agreement commenced on August 9, 2017.

 

20
 

 

Pursuant to the terms of the Gutshall Director Agreement, Mr. Gutshall shall serve as a member of the Company’s Board and will receive a stock award in such amount as determined by the Board upon the earlier of (i) 30 days from August 9, 2017 and (ii) the closing of a financing pursuant to which the Company receives a minimum of $500,000 in proceeds. In addition, Mr. Gutshall shall be reimbursed for all reasonable travel and other incidental expenses incurred in the performance of his services, including attendance at meetings, as approved by the Company.

 

Pursuant to the terms of the Gutshall Employment Agreement, Mr. Gutshall agreed to serve as Interim Chief Executive Officer and Chief Financial Officer of the Company. The initial term of the agreement will expire on August 9, 2018 and commencing on August 9, 2018 and on each anniversary of such date thereafter, the term of the Gutshall Employment Agreement shall automatically renew for one-year periods, unless earlier terminated pursuant to the terms of the Gutshall Employment Agreement. In consideration for Mr. Gutshall’s services, the Board shall determine Mr. Gutshall’s compensation upon the earlier of (i) 30 days from August 9, 2017 and (ii) the closing of a financing pursuant to which the Company receives a minimum of $500,000 in proceeds. On February 20, 2018, Mr. Rick Gutshall resigned as Interim Chief Executive Officer of the Company.

 

Effective May 15, 2019, the Board of Directors appointed Thomas Cook to act as interim principal accounting officer and principal executive officer serving in the capacity of interim CEO and interim CFO with non-material arrangements to apply moving forward, including compensation of $5,000 and 10,000 shares monthly, potential stock and other considerations, indemnifications and reimbursement of expenses. While Mr. Cook was the acting CEO and CFO, the Company sees him serving in a limited role while it is actively seeking new CEO and CFO candidates to serve on long term basis, with education and experiences to fit the Company 2020 plans. As of December 31, 2019, the Company recorded accrued management fee of $9,000. On May 11, 2020, Mr. Cook resigned his positions with the Company.

 

On August 4, 2021, the Company formalized its employment and compensation arrangement with Mr. Leslie Bocskor. Mr. Bocskor was initially engaged as CEO on May 11, 2020, at a monthly rate of $2,500 pending the establishment of a comprehensive employment and compensation agreement. To date, Mr. Bocskor has not received any consideration for his efforts, and over this time continued to bring necessary resources to the company in the form of executive and administrative support, and more as needed. These resources included several critical functions provided by individuals and entities who worked to support the CEO and the Company over the prior year to stabilize and sustain the Company and lay the foundation for future success.

 

The Board has recognized the substantive efforts of Messrs. Leslie Bocskor, Benjamin Rote, and Dennis Forchic to sustain and support the Company over the past year without compensation while laying the foundation for the future. The Board has voted to formalize employment agreements with Messrs. Bocskor and Rote, and an advisory agreement with Mr. Forchic. Stock option agreements reflecting past contributions and incentives for the future have been issued to all three parties. Stock options plans were offered with an exercise price of $0.01 and consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic vesting immediately. On the one-year anniversary of their respective agreements, additional stock options priced at $0.015 will vest with consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic.

 

Retirement Benefits

 

We do not currently provide our named executive officers with supplemental or other retirement benefits.

 

21
 

 

Outstanding Equity Awards at December 31, 2023

 

As of December 31, 2021, the Company granted stock options to Messrs. Bocskor, Rote and Forchic in recognition of their contributions. On August 4, 2021, Stock option agreements reflecting past contributions and incentives for the future have been issued to all three parties. Stock options plans were offered with an exercise price of $0.01 and consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic vesting immediately. On the 1-year anniversary of their respective agreements, additional stock options priced at $0.015 will vest with consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic.

 

Director Compensation

 

During the year ended December 31, 2022, board members Keith Crouch and Michael Blicharski were each granted the option to purchase up to 10 million shares of common stock, for a total of 20 million shares, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date. Each director is due to be paid $25,000 annually.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table illustrates the year-end potential fully diluted shares as of December 31, 2023 and 2022.

 

For the year ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

   Years ended 
   December 31, 
   2023   2022 
   (shares)   (shares) 
         
Series A Preferred Stock   0    0 
Convertible notes   507,896    0 
Stock Options   1,024,000,000    854,000,000 
Warrants   761,003,846    116,446,154 
    1,785,511,742    970,446,154 

 

The following table sets forth the ownership, as of the this date of our common stock by each person known by us to be the beneficial owner of more than 5% of our outstanding common stock, our director, and our executive officer and director as a group. To the best of our knowledge, the persons named have sole voting and investment power with respect to such shares, except as otherwise noted. There are no pending or anticipated arrangements that may cause a change in control.

 

22
 

 

The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within 60 days through the conversion or exercise of any convertible security, warrant, option or other right. More than one person may be deemed to be a beneficial owner of the same securities. The percentage of beneficial ownership by any person as of a particular date is calculated by dividing the number of shares beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting or investment power within 60 days, by the sum of the number of shares outstanding as of such date plus the number of shares as to which such person has the right to acquire voting or investment power within 60 days. Consequently, the denominator used for calculating such percentage may be different for each beneficial owner. Except as otherwise indicated below and under applicable community property laws, we believe that the beneficial owners of our common stock listed below have sole voting and investment power with respect to the shares shown. The business address of the shareholders is 7401 W. Slaughter Lane #5078, Austin, Texas 78739.

 

Certain Ownership Table(1)

 

Name 

Number of

Shares of

Common

Stock

   Percentage 
Leslie Bocskor (2)   65,552    0.002111%
Rick Gutshall (3)   758,401    0.024420%
Lang Coleman (4)   1,317,528    0.042423%
All executive officers and directors as a group (4 persons)   2,141,481    0.068953%
           
Benjamin Coleman   1,317,528    0.042423%

 

 

1. The percentages are based on the total issued common stock as of December 31, 2023 of 3,105,704,056.

2. Mr. Bocskor is both Chief Executive Officer and Chief Financial Officer.

3. Mr. Gutshall is a Director.

4. Mr. Coleman is a Director.

 

This table is based upon information derived from our stock records. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, each of the shareholders named in this table has sole or shared voting and investment power with respect to the shares indicated as beneficially owned.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

On August 4, 2021, Leslie Bocskor was appointed Chief Executive Officer. Mr. Bocskor held the position of CEO since May 20, 2020, but did not have a formal employment agreement with the Company. Pursuant to the terms of Mr. Bocskor’s employment agreement (the “Bocskor Agreement”), Mr. Bocskor receives an annual base salary of $240,000, subject to review and adjustment by the Company in its sole discretion. In connection with the Bocskor Agreement, Mr. Bocskor was also granted an option to purchase 300,000,000 shares of the Company’s common stock pursuant to a Stock Option Agreement attached as Exhibit B to the Bocskor Agreement. Mr. Bocskor served and continues to serve as Executive Chairman of Electrum Partners.

 

Mr. Bocskor is also eligible for a discretionary annual cash bonus of up to fifty (50%) percent of his base salary, subject to the Company’s sole discretion. Mr. Bocskor’s eligibility for his bonus will be dependent on his continuous performance of services to the Company and meeting certain performance targets and goals set by the Board in advance of, or within the first quarter, of each calendar year. Any bonus shall be subject to any incentive compensation plan adopted by the Company.

 

23
 

 

Weadock Employment Agreement

 

On February 20, 2018, Mr. Daniel Weadock was appointed Chief Executive Officer and Director of the Company. On February 20, 2018, the Company entered into an executive employment agreement with Mr. Weadock (the “Weadock Employment Agreement”), pursuant to which Mr. Weadock agreed to act as the Company’s chief executive officer. Pursuant to the terms of the Weadock Employment Agreement, Mr. Weadock initial will not receive a salary. However, effective on the business day after the date on which the Company achieves Capitalization (as hereinafter defined) of $2,000,000 or more, Mr. Weadock’s annual base salary will be $100,000. For purposes of the Weadock Employment Agreement, “Capitalization” means aggregate net cash proceeds received by the Company from (a) the Company’s sale of common stock pursuant to Puts (as such term is defined in the Investment Agreement dated as of October 12, 2017 by and between the Company and Tangiers Global, LLC (the “Investment Agreement”)) under the Investment Agreement, and/or (b) any other sale by the Company of common stock or preferred stock, whether in a public offering or a private placement. In addition, pursuant to the terms of the Weadock Employment Agreement, the Company agreed to grant Mr. Weadock (i) 300,000 shares of restricted stock as soon as administratively practicable following execution of the Weadock Employment Agreement, and (ii) 1,584,202 shares of restricted common stock, consistent with the grant and vesting schedule set forth in the agreement; provided, however, that no grant will be made and no shares will be issued with respect to any grant if Mr. Weadock is not employed by the Company as an executive on the respective Date of Grant as set forth in the agreement. The Weadock Employment Agreement has a term of one year, unless Mr. Weadock’s employment is terminated sooner by the board of directors, and the term will be extended for additional one-year periods unless the Company or Mr. Weadock gives the other party at least 30 days’ prior written notice of its intent not to renew. On February 20, 2018, the Company also entered into a compensation agreement with Mr. Weadock (the “Director Compensation Agreement”).Pursuant to the terms of the Director Compensation Agreement, the Company agreed to grant Mr. Weadock an aggregate of 240,000 shares of restricted common stock, consistent with the grant and vesting schedule set forth in the agreement; provided, however, that no grant will be made and no shares will be issued with respect to any grant, if Mr. Weadock is not a member of the Company’s board of directors on the respective Date of Grant as set forth in the agreement. If the Company is acquired by, or merged into and with, another entity prior to the last Date of Vesting set forth in the agreement (i.e. February 23, 2022), all shares issuable to Mr. Weadock under the Director Compensation Agreement will become fully vested and non-forfeitable. The Company also agreed to reimburse Mr. Weadock for all reasonable travel and incidental expenses incurred by Mr. Weadock in performing his services and attending meetings as approved in advance by the Company. Also, on February 20, 2018, the Company also entered into an indemnity agreement with Mr. Weadock (the “Weadock Indemnity Agreement”). Pursuant to the terms of the Indemnity Agreement, the Company agreed to use reasonable efforts to obtain and maintain in full force and effect directors’ and officers’ liability insurance (“D&O Insurance”) in reasonable amounts from established and reputable insurers; provided, however, the Company shall have no obligation to obtain or maintain D&O Insurance if the Company determines in good faith that such insurance is not reasonably available, the premium costs for such insurance are disproportionate to the amount of coverage provided, the coverage is reduced by exclusions so as to provide an insufficient benefit, or Mr. Weadock is covered by similar insurance maintained by a subsidiary of the Company. In addition the foregoing, the Company will indemnify Mr. Weadock from certain third party actions, derivative actions and actions where Mr. Weadock is decreased; provided, however, the Company shall not be obligated to indemnify Mr. Weadock for actions including, but not limited to, actions initiated by Mr. Weadock, for any action in which it is determined that the material assertions made by Mr. Weadock in such proceeding were not made in good faith or were frivolous, for any settlements not authorized by the Company, for any actions on the account of Mr. Weadock’s willful misconduct, and for any expenses and the payment of profits arising from the purchase and sale Mr. Weadock of securities in violation of Section 16(b) of the Securities Exchange Act, or any similar successor statute; provided, further that, that the Company shall not be obligated to indemnify Mr. Weadock for expenses or liabilities of any type whatsoever which have been paid directly to Mr. Weadock pursuant to the Company’s D&O Insurance policy.

 

Effective May 15, 2019, the Registrant mutually and amicably arranged with departing officer and Director Daniel Weadock, for him to transition becoming an advisor to the Registrant. Thus, Mr. Weadock no longer serves in any officer or Director capacity. As part of a non-material arrangement, subject to the Board monthly requests, Mr. Weadock focuses include consulting on potential acquisitions, among other things. The Board confirmed typical consulting arrangements to apply moving forward, including some shares of common stock, 100,000, potential future stock and other considerations, indemnifications, and reimbursement of expenses.

 

24
 

 

Management

 

Effective May 15, 2019, the Board of Directors appointed Thomas Cook to act as interim principal accounting officer and principal executive officer serving in the capacity of interim CEO and interim CFO with non-material arrangements to apply moving forward, including compensation of $5,000 and 10,000 shares monthly, potential stock and other considerations, indemnifications and reimbursement of expenses. While Mr. Cook was the acting CEO and CFO, the Company sees him serving in a limited role while it is actively seeking new CEO and CFO candidates to serve on long term basis, with education and experiences to fit the Company 2020 plans. As of December 31, 2019, the Company recorded accrued management fee of $9,000. On May 11, 2020, Mr. Cook resigned his positions with the Company.

 

Effective May 11, 2020, the Company (Registrant) mutually and amicably completed a change of officers, as to the principal accounting officer and principal executive officer, the person serving in the capacity of interim CEO and interim CFO. Mr. Cook, serving as both up to such time, departed, and no longer serves in any officer or Director capacity. The Board of Directors appointed Leslie Bocskor to act as a principal executive officer serving in the capacity of CEO with non-material arrangements to apply moving forward, including compensation of $2,500 monthly, potential stock, and other considerations, indemnifications, and reimbursement of expenses.

 

On August 4, 2021, the Company formalized its employment and compensation arrangement with Mr. Leslie Bocskor. Mr. Bocskor was initially engaged as CEO on May 11, 2020, at a monthly rate of $2,500 pending the establishment of a comprehensive employment and compensation agreement. To date, Mr. Bocskor has not received any consideration for his efforts, and over this time continued to bring necessary resources to the company in the form of executive and administrative support, and more as needed. These resources included several critical functions provided by individuals and entities who worked to support the CEO and the Company over the prior year to stabilize and sustain the Company and lay the foundation for future success.

 

The Board has recognized the substantive efforts of Messrs. Leslie Bocskor, Benjamin Rote, and Dennis Forchic to sustain and support the Company over the past year without compensation while laying the foundation for the future. The Board has voted to formalize employment agreements with Messrs. Bocskor and Rote, and an advisory agreement with Mr. Forchic. Stock option agreements reflecting past contributions and incentives for the future have been issued to all three parties. Stock options plans were offered with an exercise price of $0.01 and consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic vesting immediately. On the one-year anniversary of their respective agreements, additional stock options priced at $0.015 will vest with consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic. As of December 31, 2021, Messrs. Bocskor, Rote and Forchic had voluntarily forfeited the cash compensation portion of their compensation agreements until such time that it is in the best interests of the Company.

 

Lastly, the Board, consisting of Directors Rick Gutshall and Lang Coleman, having not received any consideration over the past 2 years, will receive stock options of 5 million options each at a price of $0.01. The company’s legal counsel will be receiving 10 million options, under the same terms as the Board, in recognition of their valuable work and support.

 

25
 

 

Convertible Promissory Note

 

On September 28, 2020, The Company entered into a Convertible Promissory Note with Electrum Partners, LLC, (the “Electrum Partners”) for $10,000 USD with a maturity of 90 days. The proceeds will be used for general corporate purposes. Electrum Partners, LLC is an entity under common control with the Company.

 

The note is convertible into shares of the Company’s common stock ninety (90) days from September 28, 2020. Note 4 is convertible at the lower conversion price of $0.002 or 65% of the lowest trading prices of the Company’s common stock during the fifteen (15) consecutive trading days prior to the date of on which a noteholder elects to convert all or part of the note. During the year ended December 31, 2021, the note was fully converted into common stock.

 

Director Independence

 

Our board of directors has determined that we do not have a board member that qualifies as “independent” as the term is used in Item 7(d)(3) (iv)(B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(15) of the NASDAQ Marketplace Rules.

 

Item 14. Principal Accountant Fees and Services.

 

WWC, Professional Corporation, was our independent auditor for the year ended December 31, 2023.

 

The following table shows the fees paid or accrued by us for the audit and other services provided by our auditor for the fiscal years ended December 31, 2023 and 2022.

 

   2023   2022 
Audit fees  $19,535   $17,500 
Audit-related fees   -    - 
Tax fees   -    - 
All other fees   -    - 
Total  $19,535   $17,500 

 

As defined by the SEC, (i) “audit fees” are fees for professional services rendered by our principal accountant for the audit of our annual financial statements and review of financial statements included in our Form 10-K, or for services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years; (ii) “audit-related fees” are fees for assurance and related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “audit fees;” (iii) “tax fees” are fees for professional services rendered by our principal accountant for tax compliance, tax advice, and tax planning; and (iv) “all other fees” are fees for products and services provided by our principal accountant, other than the services reported under “audit fees,” “audit-related fees,” and “tax fees.”

 

Under applicable SEC rules, the Audit Committee is required to pre-approve the audit and non-audit services performed by the independent auditors in order to ensure that they do not impair the auditors’ independence. The SEC’s rules specify the types of non-audit services that an independent auditor may not provide to its audit client and establish the Audit Committee’s responsibility for administration of the engagement of the independent auditors. Until such time as we have an Audit Committee in place, the Board of Directors will pre-approve the audit and non-audit services performed by the independent auditors.

 

Consistent with the SEC’s rules, the Audit Committee Charter requires that the Audit Committee review and pre-approve all audit services and permitted non-audit services provided by the independent auditors to us or any of our subsidiaries. The Audit Committee may delegate pre-approval authority to a member of the Audit Committee and if it does, the decisions of that member must be presented to the full Audit Committee at its next scheduled meeting.

 

26
 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules.

 

(a) 1. Financial Statements

 

The consolidated financial statements and Reports of Independent Registered Public Accounting Firms are listed in the “Index to Consolidated Financial Statements” on page F-1 and included on pages F-2 through F-19.

 

2. Financial Statement Schedules

 

All schedules for which provision is made in the applicable accounting regulations of the SEC are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures are contained in the financial statements included herein.

 

3. Exhibits

 

Exhibit   Description
     
2.1   Agreement and Plan of Merger and Reorganization. (Incorporated by reference to exhibit 10.1 in the Registrant’s Form 8- K filed on August 4, 2017).
     
2.2   Certificate of Merger. (Incorporated by reference to exhibit 3.1 in the Registrant’s Form 8-K filed on August 29, 2017).
     
2.3   Certificate of Correction. (Incorporated by reference to exhibit 3.1 in the Registrant’s Form 8-K filed on September 12, 2017).
     
3.1   Articles of Incorporation – Indoor Harvest, Corp. (Incorporated by reference to exhibit 3.1 in the Registrant’s Form S-1 filed on March 5, 2014).
     
3.2   Bylaws – Indoor Harvest, Corp. (Incorporated by reference to exhibit 3.2 in the Registrant’s Form S-1 filed on March 5, 2014).
     
3.4   Amended Bylaws – Indoor Harvest, Corp. (Incorporated by reference to exhibit 99.1 in the Registrant’s Form 8-K filed on May 23, 2017).
     
4.1   Form of common stock Certificate of Indoor Harvest, Corp. (Incorporated by reference to exhibit 4.1 in the Registrant’s Form S-1 filed on March 5, 2014).
     
4.2   Indoor Harvest 2015 Stock Award Plan. (Incorporated by reference to Ex. 4.3 in the Registrant’s Registration Statement on Form S-8 filed on January 21, 2015, as amended).

 

27
 

 

10.1   Executive Employment Agreement dated February 20, 2018 between Indoor Harvest Corp and Daniel Weadock. (Incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 23, 2018).
     
10.2   Compensation Agreement dated February 20, 2018 between Indoor Harvest Corp and Daniel Weadock. (Incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 23, 2018).
     
10.3   Indemnity Agreement dated February 20, 2018 by and between Indoor Harvest Corp and Daniel Weadock. (Incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 23, 2018).
     
10.4   Executive Employment Agreement dated August 4, 2021 between Indoor Harvest Corp. and Leslie Bocskor. (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 12, 2021).
     
10.5   Executive Employment Agreement dated August 4, 2021 between Indoor Harvest Corp. and Benjamin Rote. (Incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 12, 2021).
     
10.6   Advisor Agreement dated August 4, 2021 between Indoor Harvest Corp. and Dennis Forchic. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 12, 2021).
     
21.1   Subsidiary – IHC Consulting, Inc. ( SEC Form 8-K filed on August 14, 2019)
     
31.1*   Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2*   Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS*   Inline XBRL INSTANCE DOCUMENT
     
101.SCH*   Inline XBRL TAXONOMY EXTENSION SCHEMA
     
101.CAL*   Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
     
101.DEF*   Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
     
101.LAB*   Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE
     
101.PRE*   Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

 

28
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: September 4, 2024 INDOOR HARVEST CORP
     
  By: /s/ Leslie Bocskor
    Leslie Bocskor
    Chief Executive Officer
    (principal executive officer, principal financial officer, and principal accounting officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

 

Signatures   Title   Date
         
/s/ Keith Crouch   Director   September 4, 2024
Keith Crouch        
         
/s/ Michael Blicharski   Director   September 4, 2024
Michael Blicharski        

 

29
 

 

INDOOR HARVEST CORP

Consolidated Financial Statements

December 31, 2023 and 2022

 

Contents   Page
     
Reports of Independent Registered Public Accounting Firms   F-2
     
Consolidated Balance Sheets   F-4
     
Consolidated Statements of Operations and Comprehensive (Loss) Income   F-5
     
Consolidated Statements of Stockholders’ Equity   F-6
     
Consolidated Statements of Cash Flows   F-7
     
Notes to Consolidated Financial Statements   F-8

 

F-1
 

 

 

Report of Independent Registered Public Accounting Firm

 

To: The Board of Directors and Stockholders of
  Indoor Harvest Corp

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Indoor Harvest Corp and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive (loss) income, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Emphasis of Matter – Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of December 31, 2022, the Company had incurred substantial losses, and had an accumulated deficit and had net cash outflows in operating activities which gave rise to substantial doubt regarding the Company’s ability to continue as a going concern. As discussed in Note 2 to the financial statements, as of December 31, 2023, the Company’s had no cash, a negative net working capital position and continued to incur substantial losses, leading to stockholders’ deficit, and net cash outflows in operating activities; accordingly, the substantial doubt regarding the Company’s ability to continue as going concern was not alleviated and still exists; however, management is closely monitoring the situation; its plan to address this substantial doubt in set forth in Note 2. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

F-2
 

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Impairment on acquisition deposits: During the audit of the year ended December 31, 2023, auditors noted that there was a deposit paid towards an acquisition which has not been completed. We inquired management, reviewed available relevant documentation and performed analysis of the qualitative factors; it was determined that it is unlikely that the transaction will be completed. The deposit asset is neither recoverable nor is it expected to bring future benefit to the Company and that full impairment was reasonable.

 

Valuation of Stock option: As described further in Notes 6 to the financial statements, the Company granted the board members, certain consultants and advisors stock options as compensation for their services rendered. The Company utilized a Black-Scholes model to determine the fair value of the stock options, which uses certain assumptions related to exercise price, term, expected volatility, and risk-free interest rate. Auditors determined the assessment of the fair values of the stock options as a critical audit matter due to the significant judgements used by the Company in determining the fair value of the stock options. Auditing the valuation of the stock options involved a high degree of auditor judgement and specialized skills and knowledge were needed.

 

Our audit procedures consisted of the following, among others:

 

 Reviewing the stock option agreement to verify the terms and amount of the stock option issued.
Evaluating the appropriateness of the Black-Scholes model used by the Company to value the stock options.
Testing the reasonableness of the assumptions used by the Company in the Black-Scholes model including exercise price, term, expected volatility, and risk-free interest rate.
Testing the accuracy and completeness of data used by the Company in developing the assumptions used in the Black-Scholes model.

 

 
WWC, P.C.  
Certified Public Accountants  
PCAOB ID: 1171  

 

We have served as the Company’s auditor since November 26, 2019

 

San Mateo, California

July 16, 2024

 

F-3
 

 

INDOOR HARVEST CORP

Consolidated Balance Sheets

 

   December 31,   December 31, 
   2023   2022 
ASSETS          
Current Assets:          
Cash  $-   $226,231 
Notes receivable, net   -    163,588 
Prepaid expenses and other receivable   37,418    44,085 
Total Current Assets   37,418    433,904 
           
Prepayment for acquisition-related party   -    145,000 
TOTAL ASSETS  $37,418   $578,904 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (Deficit)          
Current Liabilities:          
Accounts payable and accrued liabilities  $855,991   $233,378 
Convertible note payable, net of debt discount of $0   471,094    - 
Total Current Liabilities   1,327,085    233,378 
           
Total Liabilities   1,327,085    233,378 
           
Commitments and contingencies   -    - 
           
Stockholders’ Equity (Deficit)          
Preferred stock: 15,000,000 authorized; $0.01 par value; Series A Convertible Preferred stock: 15,000,000 designated, 0 shares issued and outstanding   -    - 
Common stock: 10,000,000,000 authorized; $0.001 par value; 3,105,704,056 and 2,693,190,084 shares issued and outstanding, respectively   3,105,704    2,693,190 
Additional paid in capital   25,394,278    24,135,367 
Shares to be issued   531,000    576,000 
Accumulated deficit   (30,320,649)   (27,059,031)
Total Stockholders’ Equity (Deficit)   (1,289,667)   345,526 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (Deficit)  $37,418   $578,904 

 

The accompanying notes are an integral part of these audited consolidated financial statements.

 

F-4
 

 

INDOOR HARVEST CORP

Consolidated Statement of Operations

 

   2023   2022 
   Years Ended 
   December 31, 
   2023   2022 
         
Revenue  $-   $- 
Cost of sales   -    - 
Gross Profit (Loss)   -    - 
           
Operating Expenses          
Professional fees   1,566,940    1,567,352 
General and administrative   400,473    1,803,461 
Total Operating Expenses   1,967,413    3,370,813 
           
Loss from operations   (1,967,413)   (3,370,813)
           
Other Income (Expense)          
Interest income   3,373    7,216 
Amortization of OID   (312,500)   - 
Interest Expense   (360,788)   - 
Impairment loss   (624,289)   - 
Total other income (expenses)   (1,294,204)   7,216 
           
Loss before income taxes   (3,261,618)   (3,363,597)
           
Provision for income taxes   -    - 
           
Net loss  $(3,261,618)  $(3,363,597)
           
Comprehensive Loss  $(3,261,618)  $(3,363,597)
           
Basic and diluted income (loss) per common share          
Basic  $(0.00)  $(0.00)
Diluted  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding          
Basic   2,913,802,800    2,695,718,387 
Diluted   3,001,440,165    2,695,718,387 

 

The accompanying notes are an integral part of these audited consolidated financial statements.

 

F-5
 

 

INDOOR HARVEST CORP

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

 

   Number
of
Shares
   Amount   Number
of
Shares
   Amount   Additional
Paid in
Capital
   Share
to be
issued
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
   Series A Convertible                         
   Preferred Stock   Common Stock                 
   Number
of
Shares
   Amount   Number
of
Shares
   Amount   Additional
Paid in
Capital
   Share
to be
issued
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                                 
Balance - December 31, 2021       -            -    2,575,909,930    2,575,910    21,210,721    -    (23,695,434)              91,197 
                                         
Common stock issued for cash and warrants   -    -    116,446,154    116,446    483,554    -    -    600,000 
Common stock issued for services   -    -    834,000    834    4,166    -    -    5,000 
Stock based compensation   -    -    -    -    2,436,926    -    -    2,436,926 
Proceeds received shares to be issued   -    -    -    -    -    576,000    -    576,000 
Net loss   -    -    -    -    -         (3,363,597)   (3,363,597)
Balance - December 31, 2022   -   $-    2,693,190,084   $2,693,190   $24,135,267   $576,000   $(27,058,931)  $345,526 
                                         
Common stock issued for cash and warrant   -    -    172,230,769    172,231    524,769    (576,000   -    121,000 
Common stock issued for services   -    -    100,000,000    100,000    20,000    130,000    -    250,000 
Common stock issued for convertible note   -    -    31,250,000    31,250    218,750    -    -    250,000 
Common stock issued for default interest   -    -    109,033,203    109,033    54,517    -    -    163,550 
Stock based compensation   -    -    -    -    440,875    -    -    440,875 
Proceeds received shares to be issued             -         -    401,000        401,000
Net loss   -    -    -    -    -         (3,261,618)   (3,261,618)
Balance - December 31, 2023   -   $-    3,105,704,056   $3,105,704   $25,394,178   $531,000   $(30,320,649)  $(1,289,667)

 

The accompanying notes are an integral part of these audited consolidated financial statements.

 

F-6
 

 

INDOOR HARVEST CORP

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

         
  

Years Ended

December 31,

 
   2023   2022 
Cash Flows from Operating Activities:          
Net loss  $(3,261,618)  $(3,363,597)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization expense   312,500    - 
Interest expenses   322,144      
Impairment loss   624,289    - 
Stock based compensation   690,875    2,441,926 
Changes in operating assets and liabilities:          
Prepaid expenses and other receivable   170,256    (37,706)
Accounts payable and accrued expenses   622,613    122,876 
Due to related party   -    (33,902)
Net Cash used in Operating Activities   (518,941)   (870,403)
           
Cash Flows from Investing Activities:          
Investment in 369 Hemp   (429,289)   - 
Investment in Metabiogenix (US)   (50,000)   (160,000)
Prepayments for acquisition - related party   -    (145,000)
Net Cash used in Investing Activities   (479,289)   (305,000)
           
Cash Flows from Financing Activities:          
Proceeds from convertible note   250,000    - 
Proceeds from stock subscriptions for shares to be issued   401,000    576,000 
Proceeds from issuance of common stock and warrants   121,000    600,000 
Net Cash provided by Financing Activities   772,000    1,176,000 
           
Net change in cash   (226,231)   597
Cash, beginning of period   226,231    232,850 
Cash, end of period  $-  $226,231 
           
Supplemental Cash Flow Information          
Cash paid for interest  $-   $- 
Cash paid for taxes  $-   $- 
           
Non-Cash Investing and Financing Activities:          
Common stock and warrants issued from shares to be issued  $576,000   $- 

 

The accompanying notes are an integral part of these audited consolidated financial statements.

 

F-7
 

 

INDOOR HARVEST CORP

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations and Organization

 

Indoor Harvest Corp (the “Company,”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739. On August 3, 2017, we formed Alamo Acquisition, LLC, a wholly owned Texas limited liability company (“Alamo Acquisition Sub”). On August 4, 2017, we consummated a business acquisition (the “Alamo Acquisition”) pursuant to which Alamo Acquisition Sub acquired all of the outstanding member interests of Alamo CBD, LLC. (“Alamo CBD”), a Texas limited Liability Company. Upon closing of the Alamo Acquisition, the member interests of Alamo CBD were exchanged for 7,584,008 shares of Indoor Harvest’s common stock, the parent company of Alamo Acquisition Sub, and Alamo CBD continued as our surviving wholly-owned subsidiary, and Alamo Acquisition Sub ceased to exist. Pursuant to ASC 805 “Business Combinations,” the Company determined the Alamo Acquisition was an asset purchase.

 

From inception until August 4, 2017, the Company provided full service, state of the art design-build, engineering, procurement and construction services to the indoor and vertical farming industry. The Company provided production platforms, mechanical systems and complete custom designed build outs for both Controlled Environment Agriculture (“CEA”) and Building Integrated Agriculture (“BIA”), for two unique industries, produce and cannabis. In mid-2016, the Company began efforts to separate its produce and cannabis related operations due to ongoing feedback from both clients and potential institutional investors. It was determined that the Company’s involvement in the cannabis industry was creating conflicts for clients and potential institutional investors wishing to work with the Company from the produce industry due to the public perception and political issues surrounding the cannabis industry. By late-2016, the Company had decided to cease actively selling its products and services to the vertical farming industry and to focus on utilizing the Company’s developed technology and methods for the cannabis industry. On August 4, 2017, the Company ceased actively supporting business development of vertical farms for produce production.

 

On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis.

 

Basis of Presentation

 

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

It is management’s opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.

 

F-8
 

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant estimates include, but are not limited to, the estimate of percentage of completion on construction contracts in progress at each reporting period which we rely on as a primary basis of revenue recognition, estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Indoor Harvest Corp. and its wholly-owned subsidiaries, Alamo CBD and IHC. All significant inter-company accounts and transactions have been eliminated in consolidation.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with a maturity of three months or less to be cash and cash equivalents.

 

Stock Based Compensation

 

The Company recognizes stock-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 focuses on transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus in which an entity obtains employee services in stock-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions).

 

(Loss) Income per Share

 

Basic income (loss) per share amounts are calculated based on the weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is based on the weighted average numbers of shares of common stock outstanding for the periods, including dilutive effects of stock options, warrants granted and convertible preferred stock. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported.

 

For the years ended December 31, 2023 and 2022, respectively, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
   (shares)   (shares) 
         
Series A Preferred Stock   -    - 
Convertible notes   140,283,203    - 
Warrant   761,003,846    116,446,154 
Stock option   1,024,000,000    854,000,000 
Anti dilutive Securities   1,925,287,049    970,446,154 

 

F-9
 

 

Fair Value of Financial Instruments

 

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

 

The following table summarizes fair value measurements by level at December 31, 2023 and 2022, measured at fair value on a recurring basis:

 

December 31, 2023  Level 1   Level 2   Level 3   Total 
Assets                    
None  $-   $-   $-   $- 
                     
Liabilities                    
Convertible notes, net  $-   $-   $471,904    $471,904 

 

December 31, 2022  Level 1   Level 2   Level 3   Total 
Assets                    
Notes receivable, net  $-   $-   $163,588   $163,588 
                     
Liabilities                    
None  $-   $-   $-   $- 

 

Income Taxes

 

The Company accounts for income taxes pursuant to ASC 740—Income Taxes, which requires recognition of deferred income tax liabilities and assets for the expected future tax consequences of events that have been recognized in the financial statements or tax returns. The Company provides for deferred taxes on temporary differences between the financial statements and tax basis of assets using the enacted tax rates that are expected to apply to taxable income when the temporary differences are expected to reverse.

 

ASC 740 establishes a more-likely-than-not threshold for recognizing the benefits of tax return positions in the financial statements. Also, the statement implements a process for measuring those tax positions that meet the recognition threshold of being ultimately sustained upon examination by the taxing authorities. There are no uncertain tax positions taken by the Company on its tax returns. The Company files tax returns in the U.S. and states in which it has operations and is subject to taxation. Tax years subsequent to 2011 remain open to examination by U.S. federal and state tax jurisdictions.

 

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Reform Act”). We recognize the impact of tax legislation in the period in which the law is enacted. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Tax Reform Act. Consistent with that guidance, we recognized provisional amounts based upon our interpretation of the tax laws and estimates which require significant judgments. The actual impact of these tax laws may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in our interpretations and assumptions, additional guidance that may be issued by the government and actions we may take as a result of these enacted tax laws. Any adjustments recorded to the provisional amounts will be included in income from operations as an adjustment to tax expense.

 

F-10
 

 

Derivative Liability

 

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2023 and 2022, the Company did not have any derivative instruments that were designated as hedges.

 

Adoption of New Accounting Standards

 

Effective January 1, 2019, we adopted Accounting Standards Codification 842, Leases (“ASC 842”). Operating lease right-of-use (“ROU”) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on our consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The adoption of this standard did not have a significant impact on the financial statements.

 

Recent Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted.

 

NOTE 2 - GOING CONCERN

 

As reflected in the accompanying consolidated financial statements, the Company had net cash used in operations of $(518,941) and has an accumulated deficit of $30,320,649, for the year ended December 31, 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent on Management’s plans which include potential asset acquisitions, mergers or business combinations with other entities, further implementation of its business plan and continuing to raise funds through debt or equity financings. The Company will likely rely upon related party debt or equity financing in order to ensure the continuing existence of the business.

 

F-11
 

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities at December 31, 2023 and 2022 are as follows:

 

   December 31, 2023   December 31, 2022 
Accounts payable  $(569,844)  $(139,603)
Credit card   (6,800)   (7,877)
Accrued expenses   (213,377)   (85,898)
Accrued management fee   (29,167)   0 
Accrued interest   (36,803)   0 
Total accounts payable and accrued liabilities  $(855,991)  $(233,378)

 

NOTE 4 – CONVERTIBLE NOTES

 

On April 12, 2023, the Company’s board of directors approved to issue a convertible note of $312,500 with 20% discount, at rate of 6% per annum and maturity date shall be ninety days after issuance of note, which is July 12, 2023, with interest accruing at a rate of 15% if the Company is in default. The Company’s board of directors also deems it in the best interest of the Company to issue to the holder 31,250,000 shares of common stock and a warrant for 31,250,000 shares of common stock with exercise price of $0.01 per share subject to adjustment and for term of five years. Pursuant to the agreement, the Company obtained $180,500 in net cash after distribution of attorney and brokers fees.

 

The note holder would have the right to convert all or any part the outstanding and unpaid principal, interest, fees, or any other obligation owed pursuant to this Note into fully paid and nonassessable shares of Common Stock occurrence of any event of default at a default conversion price of $0.001 per share.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $312,500 was recorded on the note. As of December 31, 2023, unamortized debt discount was $0 and amortization of debt discount was $312,500.

 

As of December 31, 2023, the note was in default and additional principal $158,594 has been applied to the outstanding balance as interest expense, resulting an outstanding principal of $471,094 and accrued interest of $36,803. The holder was issued an additional 109,033,203 shares of common stock as default shares.

 

NOTE 5 - RELATED PARTY TRANSACTIONS

 

Management

 

During the year ended December 31, 2023 the Company recorded an impairment loss of $624,289 to impair the prepayment of $145,000 for acquisition of Electrum Partners LLC; of $429,289 deposit on acquisition of Hemp 369; and of $50,000 deposit on acquisition of MetaBioGenix

 

During the year ended December 31, 2023 and 2022, the Company paid professional fees of $1,566,940 and $1,567,352 respectively.

 

F-12
 

 

NOTE 6 - STOCKHOLDERS’ EQUITY

 

On May 11, 2020, the Company completed an increase in the authorized shares of the Company’s stock to a total number of 10,015,000,000, allocated as follows among these classes and series of stock:

 

  Common Stock Class, par value $0.001 per share - 10,000,000,000 shares authorized.
  Preferred Stock Class, Series A, par value $0.01 per share - 15,000,000 shares authorized.

 

The Company financials have been presented assuming that the increase in authorized was in effect from the first period presented.

 

On October 1, 2021, the Company converted the Electrum Partners outstanding Convertible Promissory Note of $10,000 issued September 28, 2020 into 5,125,000 restricted shares of the Company’s common stock.

 

On November 8, 2021, the Company finalized a Supplemental agreement with the Series A Preferred shareholders to convert their holdings into common shares of the Company at $0.0125 in alignment and support of the current management team’s initiatives with the goal of benefiting shareholders. This agreement was pursued for the benefit of the Company’s common shareholders to mitigate the potential risk of diluting their shareholding in the event that the Company undertakes additional financing transactions to fund the Company’s expansion initiatives.

 

Pursuant to the Preferred Shareholder’s Supplemental Agreement dated November 8, 2021 (the “Supplemental Agreement”) by and between the Company and holders of its Series A Preferred shares, under which holders of the Series A Preferred shares agreed to convert all of the Series A Preferred shares into common shares of the Company effective November 8, 2021, the Company has issued an aggregate of sixty (60) million restricted common shares. The restricted common shares issued are subject to Rule 144 required holding periods.

 

On November 8, 2021, the Company entered into subscription agreements with certain accredited investors for the sale of Sixteen Million (16,000,000) common shares of the Company, par value of $0.001 per share, for a total consideration to the Company of Two Hundred Thousand ($200,000) Dollars. The issued shares will be restricted under Rule 144 required holding periods. The Company intends to use the net proceeds from the sale for general corporate purposes and working capital.

 

On November 9, the Company converted the $25,000 10% Fixed Convertible Promissory Note, including interest, issued on August 9, 2022 into 11,388,889 common shares. The issued shares will be restricted under Rule 144 required holding periods.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

The Company has designated 15,000,000 shares of Series A Preferred Stock with a par value of $0.01.

 

The stated value of each issued share of Series A Convertible Preferred Stock shall be deemed to be $1.00, as the same may be equitably adjusted whenever there may occur a stock dividend, stock split, combination, reclassification or similar event affecting the Series A Convertible Preferred Stock. There are no dividends payable on the Series A Convertible Preferred Stock. Each holder of outstanding shares of Series A Convertible Preferred Stock shall be entitled to cast the number of votes for the Series A Convertible Preferred Stock in an amount equal to the number of whole shares of common stock into which the shares of Series A Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter

 

The Series A Preferred Stock also had a “down-round” protection feature provided to the investors if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $1.00 per common share. The conversion price would be automatically adjustable down to the price of the instrument being issued. As a result of conversion during the year ended December 31, 2020, the Series A Preferred Stock conversion price was reset to $0.00006 per share.

 

Upon any liquidation, dissolution or winding-up of the Company under Texas law, whether voluntary or involuntary, the holders of the shares of Series A Convertible Preferred Stock shall be paid an amount equal to the aggregate stated value of their shares of Series A Convertible Preferred Stock, before any payment shall be paid to the holders of common stock, or any other stock ranking on liquidation junior to the Series A Convertible Preferred Stock, an amount for each share of Series A Convertible Preferred Stock held by such holder equal to the sum of the Stated Value thereof.

 

On August 27, 2021, the Company completed an initiative when it entered into a Modification Agreement (the “Modification”) in cooperation with the current Series A Preferred shareholders to modify their conversion privileges to align and support current management team initiatives and shareholder interests. The modification agreement provides the Preferred shareholders the ability to convert into common shares at a conversion price at the lower of $0.40 (per the original agreement), or the subsequent per share pricing of a future equity raise greater than Five Hundred Thousand ($500,000) Dollars. On November 8, 2021, the Company amended the conversion price to $0.0125. This Modification is forecasted to support anti- dilutive measures potentially to the benefit of our shareholders and may allow the Company to proceed with plans relating to funding needs.

 

During the year ended December 31, 2021, 750,000 shares of Series A Convertible Preferred Stock were converted into 60,000,000 shares of common stock. The corresponding derivative liability at the date of conversion of $738,000 was settled through additional paid in capital.

 

As of December 31, 2023 and 2022, there were zero shares of Series A Convertible Preferred Stock issued and outstanding.

 

F-13
 

 

Common Stock

 

Each common stock entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

 

During the year ended December 31, 2022, the Company issued 117,280,154 shares of common stock as follows:

 

  116,446,154 shares of common stock for the private placements at $0.005 and $0.0065 per share for cash of $600,000.
  834,000 shares for consulting service valued at $5,000.

 

During the year ended December 31,2023, the Company issued 412,513,972 shares of common stock as follows:

 

  172,230,769 Shares of common stock for the private placements at $0.001,$0.000375, $0.0065 per share for cash of $524,769
  100,000,000 Shares of common stock for consulting services valued at $20,000.
  31,250,000 shares of common stock for a convertible note of $312,500.
  109,033,203 shares of common stock for default interest

 

Private Placement

 

On February 16, 2022 and March 16, 2022, the Company initiated a private placement offering for the sale of up to 150,000,000 shares of the Company’s common stock, at price of $0.006 per share, for total consideration to the Company of $900,000. On May 12, 2022, the issuance price was updated to $0.005 per share.

 

On August 1, 2022, the Company initiated a private placement offering for the sale of up to 123,076,923 shares of the Company’s common stock, at price of $0.0065 per share and an equal number of Warrants with an exercise price of $0.013 for total consideration to the Company of $800,000. On August 12, 2022 and November 9, 2022, the number shares was increased to 153,846,154 (for total consideration to the Company of $1,000,000) and 200,000,000 shares (for total consideration to the Company of $1,300,000) an equal number of Warrants with an exercise price of $0.013, respectively.

 

As of December 31, 2023, and 2022, there were 3,105,704,056 and 2,693,190,084 shares of Common Stock issued and outstanding, respectively.

 

Shares to be Issued

 

During the year ended December 31, 2022, in connection with the mentioned private placements offering in August and November 2022, the Company received $576,000 in cash proceeds. During February 2023, the Company issued restricted common shares and warrants pursuant to the closing of the August 2022 Offering totaling 89,230,769 million restricted common shares and 190,323,692 million warrants. The Shares will be restricted securities and subject to required holding periods under Rule 144.

 

During the year ended December 31, 2023, the Company received $401,000 in cash proceeds.

 

F-14
 

 

Stock Options

 

On August 4, 2021, the Board has recognized the substantive efforts of Messrs. Leslie Bocskor, Benjamin Rote, and Dennis Forchic to sustain and support the Company over the past year without compensation while laying the foundation for the future. The Board has voted to formalize employment agreements with Messrs. Bocskor and Rote, and an advisory agreement with Mr. Forchic. Stock option agreements reflecting past contributions and incentives for the future have been issued to all three parties. Stock options plans were offered with an exercise price of $0.01 and consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic vesting immediately. On the 1-year anniversary of their respective agreements, additional stock options priced at $0.015 will vest with consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic.

 

In addition, the Board, consisting of Directors Rick Gutshall and Lang Coleman, having not received any consideration over the past 2 years, will receive stock options of 5 million options each at a price of $0.01 vesting immediately. The company’s legal counsel will be receiving 10 million options at a price of $0.01 vesting immediately, under the same terms as the Board, in recognition of their valuable work and support.

 

During the year ended December 31, 2022, board members Keith Crouch and Michael Blicharski were each granted the option to purchase up to 10 million shares of common stock, for a total of 20 million shares, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

During the year ended December 31, 2023, the Company granted a total of 170 million shares of stock options to the advisors as their compensation for service providing, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

Valuation

 

The Company utilizes the Black-Scholes model to value its stock options. The Company utilized the following assumptions:

 

   Year ended   Year ended 
   December 31, 2023   December 31, 2022 
Expected term   2.66 - 5.50 years    0.06-0.50 years 
Expected average volatility   180 - 203%   146%-389%
Expected dividend yield   -    - 
Risk-free interest rate   0.67 - 3.79%   0.07-0.27%

 

During the year ended December 31, 2021, the Company granted 820,000,000 options valued at $8,004,855. During the year ended December 31, 2021, the Company recognized stock option expense of $5,728,701, of which $5,631,014 was to related parties, and as of December 31, 2021, $2,276,154 remains unamortized, of which $2,276,154 is with related parties. The intrinsic value of the 820,000,000 options outstanding as of December 31, 2021 is $210,000.

 

During the year ended December 31, 2022, board members Keith Crouch and Michael Blicharski were each granted the option to purchase up to 10 million shares of common stock, for a total of 20 million shares, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

On December 20, 2022, the Company entered into a consulting agreement for general business strategy for the period of one year and a stock option agreement for compensation of services which were granted the option to purchase up to 14 million shares of common stock, at a price of $0.01 per share of common stock. Such options will vest quarterly on March 30,2023, June 30,2023 and balance on December 20,2022, with the first quarter vesting upon the grant date.

 

During the year ended December 31, 2022, the Company recognized stock option expense of $2,436,926, of which $2,420,730 was to related parties, and as of December 31, 2022, $96,777 remains unamortized, of which $48,188 is with related parties. The intrinsic value of the 854,000,000 options outstanding as of December 31, 2022, was $0

 

During the year ended December 31, 2023, the Company granted a total of 170 million shares of stock options to the advisors as their compensation for service providing, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

During the year ended December 31, 2023, the Company recognized stock option expense of $440,875, of which $48,318 was to related parties, and as of December 31, 2023, $115,205 remains unamortized. The intrinsic value of the 1,024,000,000 options outstanding as of December 31, 2023, was $0

 

F-15
 

 

The following is a summary of stock option activity during the year ended December 31, 2023:

 

   Options Outstanding   Weighted     
   Number of   Weighted Average  

Average

Remaining life

   Fair value 
   Options   Exercise Price   (years)   on Grant Date 
                 
Outstanding, December 31, 2020   -   $-    -   $- 
Granted   820,000,000    0.012    10.00    8,004,855 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2021   820,000,000   $0.012    9.60   $8,004,855 
Granted   34,000,000    0.010    7.95    256,032 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2022   854,000,000   $0.010    8.77   $8,260,887 
Granted   170,000,000    0.012    7.09    460,820 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2023   1,024,000,000    0.012    7.09#  $8,721,707 
                     
Exercisable options, December 31, 2023   1,024,000,000   $0.012    7.09   $8,721,707 

 

Warrants

 

As part of the February 16, 2022 private placement, the Company granted warrants, which provides the option to purchase one common share for each common share purchased. The warrants issued have an exercise price of $0.01 per warrant and expire five years from the date of grant. A total of 104,600,000 warrants were granted.

 

As part of the August 12, 2022 private placement, the Company granted warrants, which provides the option to purchase one common share for each common share purchased. The warrants issued have an exercise price of $0.013 per warrant and expire five years from the date of grant. A total of 11,846,154 warrants were granted.

 

As of December 31, 2023, an investor warrant total of 644,557,692 shares of common stock was issued at an average price of $0.006 per share of common stock.

 

The following is a summary of warrant activity during the year ended December 31, 2023:

 

   Warrants Outstanding   Weighted      
   Number of   Weighted Average   Average
Remaining life
   Fair value 
   Warrants   Exercise Price   (years)   on Grant Date 
Outstanding, December 31, 2021   -   $-    -    - 
Granted   116,446,154    0.010    5.00   $726,662 
Exercised   -    -    -      
Forfeited/canceled   -    -    -      
Outstanding, December 31, 2022   116,446,154   $0.010    4.38   $726,662 
Granted   644,557,692    0.006    5.00    3,402,881 
Exercised   -    -           
Forfeited/canceled   -    -           
Outstanding, December, 2023   761,003,846   $0.007    4.19   $4,129,543 

 

The intrinsic value of the warrant outstanding as of December 31, 2023 is $0.

 

NOTE 7 - INCOME TAXES

 

Indoor Harvest operates in the United States; accordingly, federal and state income taxes have been provided based upon the tax laws and rates of the US. Deferred taxes are determined based on the temporary differences between the financial statement and income tax bases of assets and liabilities as measured by the enacted tax rates, which will be in effect when these differences reverse.

 

The components of deferred income tax assets and liabilities as of December 31, 2023 and 2022 are as follows:

 

   2023   2022 
         
Deferred tax assets          
Net operating losses  $4,096,307   $3,608,093 
Deferred tax liabilities          
Accelerated tax depreciation   -    - 
Net deferred tax assets   4,096,307    3,608,093 
           
Less: Valuation allowance   (4,096,307)   (3,608,093)
Net  $-   $- 

 

At December 31, 2023 and 2022, the Company has provided a full valuation allowance for the deferred tax assets.

 

At December 31, 2023, the Company had $19,506,224 of net operating losses (“NOLs”). NOLs generated in tax years prior to July 31, 2018, can be carryforward for twenty years, whereas NOLs generated after July 31, 2018 can be carryforward indefinitely.

 

The NOLs carry forwards are subject to certain limitations due to the change in control of the Company pursuant to Internal Revenue Code Section 382.The Company experienced a change in control for tax purposes in 2017 as a result of the merger with Alamo CBD. Accordingly, the future utilization of NOLs will be severely restricted by Section 382 of the Internal Revenue Code. Management is in the process of assessing this impact.

 

F-16
 

 

NOTE 8 - NET (LOSS) INCOME PER COMMON SHARE

 

Basic net income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods. Diluted net income per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of convertible preferred stock and convertible notes that are computed using the if-converted method, and outstanding warrants that are computed using the treasury stock method. Antidilutive stock awards consist of stock options that would have been antidilutive in the application of the treasury stock method.

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Numerator:        
Net income (loss)  $(3,261,618)  $(3,363,597)
Net income (loss) - diluted  $(3,261,618)  $(3,363,597)
           
Denominator:          
Weighted average common shares outstanding   2,913,802,800    2,695,718,387 
Effect of dilutive shares   86,862,323    - 
Diluted   3,001,440,165    2,695,718,387 
           
Net income (loss) per common share:          
Basic  $(0.00)  $(0.00)
Diluted  $(0.00)  $(0.00)

 

For the year ended December 31, 2023, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

 

NOTE 9 - SUBSEQUENT EVENTS

 

The Company evaluates subsequent events that have occurred after the balance sheet date of December 31, 2023 and up through July 16, 2024, which is the date that these financial statements are available to be issued. There are two types of subsequent events: (i) recognized, or those that provide additional evidence with respect to conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (ii) non-recognized, or those that provide evidence with respect to conditions that did not exist at the date of the balance sheet but arose subsequent to that date.

 

On February 27, 2024, the Company entered into an advisory agreement with Pacific Capital Markets LLC. Pursuant to the agreement, the company issued 100,000,000 restricted common Rule 144 shares in leiu of $100,000 cash payment for services to be rendered and performed by Pacific Capital Markets, LLC during the term of this agreement. Pacific Capital Markets, LLC is going to be advising the Company on capital formation and communications.

 

On June 19, 2024, the Company entered into an agreement with an advisor. The company agreed to issue 100,000,000 shares of common stock to the advisor and additionally pay $10,000 cash per month for one year with the ability to renew at Company’s sole and absolute discretion at the end of each year. The Advisor has had experience with certain segments of the population based on ethnicity and is advising the company on Business Development and Capital Formation in the community they have experience with.

 

F-17

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Leslie Bocskor, certify that:

 

1. I have reviewed this annual report on Form 10-K/A for the year ended December 31, 2023 of Indoor Harvest, Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: September 4, 2024  
   
/s/ Leslie Bocskor  
Leslie Bocskor  

Chief Executive Officer

(principal executive officer)

 

 

 

 

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Leslie Bocskor, certify that:

 

1. I have reviewed this annual report on Form 10-K/A for the year ended December 31, 2023 of Indoor Harvest, Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: September 4, 2024  
   
/s/ Leslie Bocskor  
Leslie Bocskor  
Chief Financial Officer  
(principal financial officer)  

 

 

 

 

Exhibit 32.1

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of Indoor Harvest, Corp. (the “Company”) on Form 10-K/A for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leslie Bocskor, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: September 4, 2024 /s/ Leslie Bocskor
  Leslie Bocskor, CEO
  Chief Executive Officer

 

 

 

 

Exhibit 32.2

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of Indoor Harvest, Corp. (the “Company”) on Form 10-K/A for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leslie Bocskor , Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: September 4, 2024 /s/ Leslie Bocskor
  Leslie Bocskor, CFO
  Chief Financial Officer (Interim)

 

 

 

v3.24.2.u1
Cover - USD ($)
12 Months Ended
Dec. 31, 2023
Jun. 28, 2024
Cover [Abstract]    
Document Type 10-K/A  
Amendment Flag true  
Amendment Description This Amendment NO. 2 to our Annual Report on Form-10K for the year ended December 31, 2023, amends in its entirety the Annual Report on Form 10-K that was originally filed on July 1st, 2024 (the “Annual Report”), to:    ● comply with (17 CFR 240), WHICH REQUIRES ANNUAL FINANCIAL STATEMENTS included in annual reports on Form 10-K to be reviewed by an independent public accountant using professional standards and procedures for conducting such reviews, as established by PCAOB,         ● to update financial statements and various other disclosures throughout this quarterly report,         ● to include the required certifications of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act, and,         ● to include exhibit 101, for XBRL (eXtensible Business Reporting Language) files.   This Amendment No. 1 revises the original filing of the Original Report and does not otherwise reflect events that may have occurred subsequent to the original filing date.    
Document Annual Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2023  
Document Fiscal Period Focus FY  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-55594  
Entity Registrant Name INDOOR HARVEST CORP  
Entity Central Index Key 0001572565  
Entity Tax Identification Number 45-5577364  
Entity Incorporation, State or Country Code TX  
Entity Address, Address Line One 7401 W. Slaughter Lane #5078  
Entity Address, City or Town Austin  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 78739  
City Area Code 512  
Local Phone Number 309-1776  
Title of 12(g) Security Common Stock, par value $0.001 per share  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status No  
Entity Interactive Data Current No  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Public Float $ 3,105,704  
Entity Common Stock, Shares Outstanding   3,205,704,056
ICFR Auditor Attestation Flag false  
Document Financial Statement Error Correction [Flag] false  
Auditor Name WWC, P.C.  
Auditor Firm ID 1171  
Auditor Location San Mateo, California  
v3.24.2.u1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current Assets:    
Cash $ 226,231
Notes receivable, net 163,588
Prepaid expenses and other receivable 37,418 44,085
Total Current Assets 37,418 433,904
Prepayment for acquisition-related party 145,000
TOTAL ASSETS 37,418 578,904
Current Liabilities:    
Accounts payable and accrued liabilities 855,991 233,378
Convertible note payable, net of debt discount of $0 471,094
Total Current Liabilities 1,327,085 233,378
Total Liabilities 1,327,085 233,378
Commitments and contingencies
Stockholders’ Equity (Deficit)    
Preferred stock: 15,000,000 authorized; $0.01 par value; Series A Convertible Preferred stock: 15,000,000 designated, 0 shares issued and outstanding
Common stock: 10,000,000,000 authorized; $0.001 par value; 3,105,704,056 and 2,693,190,084 shares issued and outstanding, respectively 3,105,704 2,693,190
Additional paid in capital 25,394,278 24,135,367
Shares to be issued 531,000 576,000
Accumulated deficit (30,320,649) (27,059,031)
Total Stockholders’ Equity (Deficit) (1,289,667) 345,526
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (Deficit) $ 37,418 $ 578,904
v3.24.2.u1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Convertible note payable, net of debt discount $ 0 $ 0
Common stock, shares authorized 10,000,000,000 10,000,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued 3,105,704,056 2,693,190,084
Common stock, shares outstanding 3,105,704,056 2,693,190,084
Series A Convertible Preferred Stock [Member]    
Preferred Stock, shares authorized 15,000,000 15,000,000
Preferred Stock, par value $ 0.01 $ 0.01
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
v3.24.2.u1
Consolidated Statement of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenue
Cost of sales
Gross Profit (Loss)
Operating Expenses    
Professional fees 1,566,940 1,567,352
General and administrative 400,473 1,803,461
Total Operating Expenses 1,967,413 3,370,813
Loss from operations (1,967,413) (3,370,813)
Other Income (Expense)    
Interest income 3,373 7,216
Amortization of OID (312,500)
Interest Expense (360,788)
Impairment loss (624,289)
Total other income (expenses) (1,294,204) 7,216
Loss before income taxes (3,261,618) (3,363,597)
Provision for income taxes
Net loss (3,261,618) (3,363,597)
Comprehensive Loss $ (3,261,618) $ (3,363,597)
Basic and diluted income (loss) per common share    
Basic $ (0.00) $ (0.00)
Diluted $ (0.00) $ (0.00)
Weighted average number of common shares outstanding    
Basic 2,913,802,800 2,695,718,387
Diluted 3,001,440,165 2,695,718,387
v3.24.2.u1
Consolidated Statements of Stockholders' Equity - USD ($)
Series A Convertible Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Payable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 2,575,910 $ 21,210,721 $ (23,695,434) $ 91,197
Balance, shares at Dec. 31, 2021 2,575,909,930        
Common stock issued for cash and warrant $ 116,446 483,554 600,000
Common stock issued for cash and warrants, shares   116,446,154        
Common stock issued for services $ 834 4,166 5,000
Common stock issued for services, shares   834,000        
Stock based compensation 2,436,926 2,436,926
Proceeds received shares to be issued 576,000 576,000
Net loss   (3,363,597) (3,363,597)
Balance at Dec. 31, 2022 $ 2,693,190 24,135,267 576,000 (27,058,931) 345,526
Balance, shares at Dec. 31, 2022 2,693,190,084        
Common stock issued for cash and warrant $ 172,231 524,769 (576,000) 121,000
Common stock issued for cash and warrants, shares   172,230,769        
Common stock issued for services $ 100,000 20,000 130,000 250,000
Common stock issued for services, shares   100,000,000        
Stock based compensation 440,875 440,875
Proceeds received shares to be issued     401,000   401,000
Net loss   (3,261,618) (3,261,618)
Common stock issued for convertible note $ 31,250 218,750 250,000
Common stock issued for convertible note, shares   31,250,000        
Common stock issued for default interest $ 109,033 54,517 163,550
Common stock issued for default interest, shares   109,033,203        
Balance at Dec. 31, 2023 $ 3,105,704 $ 25,394,178 $ 531,000 $ (30,320,649) $ (1,289,667)
Balance, shares at Dec. 31, 2023 3,105,704,056        
v3.24.2.u1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash Flows from Operating Activities:    
Net loss $ (3,261,618) $ (3,363,597)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization expense 312,500
Interest expenses 322,144  
Impairment loss 624,289
Stock based compensation 690,875 2,441,926
Changes in operating assets and liabilities:    
Prepaid expenses and other receivable 170,256 (37,706)
Accounts payable and accrued expenses 622,613 122,876
Due to related party (33,902)
Net Cash used in Operating Activities (518,941) (870,403)
Cash Flows from Investing Activities:    
Investment in 369 Hemp (429,289)
Investment in Metabiogenix (US) (50,000) (160,000)
Prepayments for acquisition - related party (145,000)
Net Cash used in Investing Activities (479,289) (305,000)
Cash Flows from Financing Activities:    
Proceeds from convertible note 250,000
Proceeds from stock subscriptions for shares to be issued 401,000 576,000
Proceeds from issuance of common stock and warrants 121,000 600,000
Net Cash provided by Financing Activities 772,000 1,176,000
Net change in cash (226,231) 597
Cash, beginning of period 226,231 232,850
Cash, end of period 226,231
Supplemental Cash Flow Information    
Cash paid for interest
Cash paid for taxes
Non-Cash Investing and Financing Activities:    
Common stock and warrants issued from shares to be issued $ 576,000
v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations and Organization

 

Indoor Harvest Corp (the “Company,”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739. On August 3, 2017, we formed Alamo Acquisition, LLC, a wholly owned Texas limited liability company (“Alamo Acquisition Sub”). On August 4, 2017, we consummated a business acquisition (the “Alamo Acquisition”) pursuant to which Alamo Acquisition Sub acquired all of the outstanding member interests of Alamo CBD, LLC. (“Alamo CBD”), a Texas limited Liability Company. Upon closing of the Alamo Acquisition, the member interests of Alamo CBD were exchanged for 7,584,008 shares of Indoor Harvest’s common stock, the parent company of Alamo Acquisition Sub, and Alamo CBD continued as our surviving wholly-owned subsidiary, and Alamo Acquisition Sub ceased to exist. Pursuant to ASC 805 “Business Combinations,” the Company determined the Alamo Acquisition was an asset purchase.

 

From inception until August 4, 2017, the Company provided full service, state of the art design-build, engineering, procurement and construction services to the indoor and vertical farming industry. The Company provided production platforms, mechanical systems and complete custom designed build outs for both Controlled Environment Agriculture (“CEA”) and Building Integrated Agriculture (“BIA”), for two unique industries, produce and cannabis. In mid-2016, the Company began efforts to separate its produce and cannabis related operations due to ongoing feedback from both clients and potential institutional investors. It was determined that the Company’s involvement in the cannabis industry was creating conflicts for clients and potential institutional investors wishing to work with the Company from the produce industry due to the public perception and political issues surrounding the cannabis industry. By late-2016, the Company had decided to cease actively selling its products and services to the vertical farming industry and to focus on utilizing the Company’s developed technology and methods for the cannabis industry. On August 4, 2017, the Company ceased actively supporting business development of vertical farms for produce production.

 

On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis.

 

Basis of Presentation

 

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

It is management’s opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.

 

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant estimates include, but are not limited to, the estimate of percentage of completion on construction contracts in progress at each reporting period which we rely on as a primary basis of revenue recognition, estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Indoor Harvest Corp. and its wholly-owned subsidiaries, Alamo CBD and IHC. All significant inter-company accounts and transactions have been eliminated in consolidation.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with a maturity of three months or less to be cash and cash equivalents.

 

Stock Based Compensation

 

The Company recognizes stock-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 focuses on transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus in which an entity obtains employee services in stock-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions).

 

(Loss) Income per Share

 

Basic income (loss) per share amounts are calculated based on the weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is based on the weighted average numbers of shares of common stock outstanding for the periods, including dilutive effects of stock options, warrants granted and convertible preferred stock. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported.

 

For the years ended December 31, 2023 and 2022, respectively, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
   (shares)   (shares) 
         
Series A Preferred Stock   -    - 
Convertible notes   140,283,203    - 
Warrant   761,003,846    116,446,154 
Stock option   1,024,000,000    854,000,000 
Anti dilutive Securities   1,925,287,049    970,446,154 

 

 

Fair Value of Financial Instruments

 

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

 

The following table summarizes fair value measurements by level at December 31, 2023 and 2022, measured at fair value on a recurring basis:

 

December 31, 2023  Level 1   Level 2   Level 3   Total 
Assets                    
None  $-   $-   $-   $- 
                     
Liabilities                    
Convertible notes, net  $-   $-   $471,904    $471,904 

 

December 31, 2022  Level 1   Level 2   Level 3   Total 
Assets                    
Notes receivable, net  $-   $-   $163,588   $163,588 
                     
Liabilities                    
None  $-   $-   $-   $- 

 

Income Taxes

 

The Company accounts for income taxes pursuant to ASC 740—Income Taxes, which requires recognition of deferred income tax liabilities and assets for the expected future tax consequences of events that have been recognized in the financial statements or tax returns. The Company provides for deferred taxes on temporary differences between the financial statements and tax basis of assets using the enacted tax rates that are expected to apply to taxable income when the temporary differences are expected to reverse.

 

ASC 740 establishes a more-likely-than-not threshold for recognizing the benefits of tax return positions in the financial statements. Also, the statement implements a process for measuring those tax positions that meet the recognition threshold of being ultimately sustained upon examination by the taxing authorities. There are no uncertain tax positions taken by the Company on its tax returns. The Company files tax returns in the U.S. and states in which it has operations and is subject to taxation. Tax years subsequent to 2011 remain open to examination by U.S. federal and state tax jurisdictions.

 

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Reform Act”). We recognize the impact of tax legislation in the period in which the law is enacted. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Tax Reform Act. Consistent with that guidance, we recognized provisional amounts based upon our interpretation of the tax laws and estimates which require significant judgments. The actual impact of these tax laws may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in our interpretations and assumptions, additional guidance that may be issued by the government and actions we may take as a result of these enacted tax laws. Any adjustments recorded to the provisional amounts will be included in income from operations as an adjustment to tax expense.

 

 

Derivative Liability

 

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2023 and 2022, the Company did not have any derivative instruments that were designated as hedges.

 

Adoption of New Accounting Standards

 

Effective January 1, 2019, we adopted Accounting Standards Codification 842, Leases (“ASC 842”). Operating lease right-of-use (“ROU”) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on our consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The adoption of this standard did not have a significant impact on the financial statements.

 

Recent Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted.

 

v3.24.2.u1
GOING CONCERN
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 - GOING CONCERN

 

As reflected in the accompanying consolidated financial statements, the Company had net cash used in operations of $(518,941) and has an accumulated deficit of $30,320,649, for the year ended December 31, 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent on Management’s plans which include potential asset acquisitions, mergers or business combinations with other entities, further implementation of its business plan and continuing to raise funds through debt or equity financings. The Company will likely rely upon related party debt or equity financing in order to ensure the continuing existence of the business.

 

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

v3.24.2.u1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities at December 31, 2023 and 2022 are as follows:

 

   December 31, 2023   December 31, 2022 
Accounts payable  $(569,844)  $(139,603)
Credit card   (6,800)   (7,877)
Accrued expenses   (213,377)   (85,898)
Accrued management fee   (29,167)   0 
Accrued interest   (36,803)   0 
Total accounts payable and accrued liabilities  $(855,991)  $(233,378)

 

v3.24.2.u1
CONVERTIBLE NOTES
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES

NOTE 4 – CONVERTIBLE NOTES

 

On April 12, 2023, the Company’s board of directors approved to issue a convertible note of $312,500 with 20% discount, at rate of 6% per annum and maturity date shall be ninety days after issuance of note, which is July 12, 2023, with interest accruing at a rate of 15% if the Company is in default. The Company’s board of directors also deems it in the best interest of the Company to issue to the holder 31,250,000 shares of common stock and a warrant for 31,250,000 shares of common stock with exercise price of $0.01 per share subject to adjustment and for term of five years. Pursuant to the agreement, the Company obtained $180,500 in net cash after distribution of attorney and brokers fees.

 

The note holder would have the right to convert all or any part the outstanding and unpaid principal, interest, fees, or any other obligation owed pursuant to this Note into fully paid and nonassessable shares of Common Stock occurrence of any event of default at a default conversion price of $0.001 per share.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $312,500 was recorded on the note. As of December 31, 2023, unamortized debt discount was $0 and amortization of debt discount was $312,500.

 

As of December 31, 2023, the note was in default and additional principal $158,594 has been applied to the outstanding balance as interest expense, resulting an outstanding principal of $471,094 and accrued interest of $36,803. The holder was issued an additional 109,033,203 shares of common stock as default shares.

 

v3.24.2.u1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 5 - RELATED PARTY TRANSACTIONS

 

Management

 

During the year ended December 31, 2023 the Company recorded an impairment loss of $624,289 to impair the prepayment of $145,000 for acquisition of Electrum Partners LLC; of $429,289 deposit on acquisition of Hemp 369; and of $50,000 deposit on acquisition of MetaBioGenix

 

During the year ended December 31, 2023 and 2022, the Company paid professional fees of $1,566,940 and $1,567,352 respectively.

 

 

v3.24.2.u1
STOCKHOLDERS’ EQUITY
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 6 - STOCKHOLDERS’ EQUITY

 

On May 11, 2020, the Company completed an increase in the authorized shares of the Company’s stock to a total number of 10,015,000,000, allocated as follows among these classes and series of stock:

 

  Common Stock Class, par value $0.001 per share - 10,000,000,000 shares authorized.
  Preferred Stock Class, Series A, par value $0.01 per share - 15,000,000 shares authorized.

 

The Company financials have been presented assuming that the increase in authorized was in effect from the first period presented.

 

On October 1, 2021, the Company converted the Electrum Partners outstanding Convertible Promissory Note of $10,000 issued September 28, 2020 into 5,125,000 restricted shares of the Company’s common stock.

 

On November 8, 2021, the Company finalized a Supplemental agreement with the Series A Preferred shareholders to convert their holdings into common shares of the Company at $0.0125 in alignment and support of the current management team’s initiatives with the goal of benefiting shareholders. This agreement was pursued for the benefit of the Company’s common shareholders to mitigate the potential risk of diluting their shareholding in the event that the Company undertakes additional financing transactions to fund the Company’s expansion initiatives.

 

Pursuant to the Preferred Shareholder’s Supplemental Agreement dated November 8, 2021 (the “Supplemental Agreement”) by and between the Company and holders of its Series A Preferred shares, under which holders of the Series A Preferred shares agreed to convert all of the Series A Preferred shares into common shares of the Company effective November 8, 2021, the Company has issued an aggregate of sixty (60) million restricted common shares. The restricted common shares issued are subject to Rule 144 required holding periods.

 

On November 8, 2021, the Company entered into subscription agreements with certain accredited investors for the sale of Sixteen Million (16,000,000) common shares of the Company, par value of $0.001 per share, for a total consideration to the Company of Two Hundred Thousand ($200,000) Dollars. The issued shares will be restricted under Rule 144 required holding periods. The Company intends to use the net proceeds from the sale for general corporate purposes and working capital.

 

On November 9, the Company converted the $25,000 10% Fixed Convertible Promissory Note, including interest, issued on August 9, 2022 into 11,388,889 common shares. The issued shares will be restricted under Rule 144 required holding periods.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

The Company has designated 15,000,000 shares of Series A Preferred Stock with a par value of $0.01.

 

The stated value of each issued share of Series A Convertible Preferred Stock shall be deemed to be $1.00, as the same may be equitably adjusted whenever there may occur a stock dividend, stock split, combination, reclassification or similar event affecting the Series A Convertible Preferred Stock. There are no dividends payable on the Series A Convertible Preferred Stock. Each holder of outstanding shares of Series A Convertible Preferred Stock shall be entitled to cast the number of votes for the Series A Convertible Preferred Stock in an amount equal to the number of whole shares of common stock into which the shares of Series A Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter

 

The Series A Preferred Stock also had a “down-round” protection feature provided to the investors if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $1.00 per common share. The conversion price would be automatically adjustable down to the price of the instrument being issued. As a result of conversion during the year ended December 31, 2020, the Series A Preferred Stock conversion price was reset to $0.00006 per share.

 

Upon any liquidation, dissolution or winding-up of the Company under Texas law, whether voluntary or involuntary, the holders of the shares of Series A Convertible Preferred Stock shall be paid an amount equal to the aggregate stated value of their shares of Series A Convertible Preferred Stock, before any payment shall be paid to the holders of common stock, or any other stock ranking on liquidation junior to the Series A Convertible Preferred Stock, an amount for each share of Series A Convertible Preferred Stock held by such holder equal to the sum of the Stated Value thereof.

 

On August 27, 2021, the Company completed an initiative when it entered into a Modification Agreement (the “Modification”) in cooperation with the current Series A Preferred shareholders to modify their conversion privileges to align and support current management team initiatives and shareholder interests. The modification agreement provides the Preferred shareholders the ability to convert into common shares at a conversion price at the lower of $0.40 (per the original agreement), or the subsequent per share pricing of a future equity raise greater than Five Hundred Thousand ($500,000) Dollars. On November 8, 2021, the Company amended the conversion price to $0.0125. This Modification is forecasted to support anti- dilutive measures potentially to the benefit of our shareholders and may allow the Company to proceed with plans relating to funding needs.

 

During the year ended December 31, 2021, 750,000 shares of Series A Convertible Preferred Stock were converted into 60,000,000 shares of common stock. The corresponding derivative liability at the date of conversion of $738,000 was settled through additional paid in capital.

 

As of December 31, 2023 and 2022, there were zero shares of Series A Convertible Preferred Stock issued and outstanding.

 

 

Common Stock

 

Each common stock entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

 

During the year ended December 31, 2022, the Company issued 117,280,154 shares of common stock as follows:

 

  116,446,154 shares of common stock for the private placements at $0.005 and $0.0065 per share for cash of $600,000.
  834,000 shares for consulting service valued at $5,000.

 

During the year ended December 31,2023, the Company issued 412,513,972 shares of common stock as follows:

 

  172,230,769 Shares of common stock for the private placements at $0.001,$0.000375, $0.0065 per share for cash of $524,769
  100,000,000 Shares of common stock for consulting services valued at $20,000.
  31,250,000 shares of common stock for a convertible note of $312,500.
  109,033,203 shares of common stock for default interest

 

Private Placement

 

On February 16, 2022 and March 16, 2022, the Company initiated a private placement offering for the sale of up to 150,000,000 shares of the Company’s common stock, at price of $0.006 per share, for total consideration to the Company of $900,000. On May 12, 2022, the issuance price was updated to $0.005 per share.

 

On August 1, 2022, the Company initiated a private placement offering for the sale of up to 123,076,923 shares of the Company’s common stock, at price of $0.0065 per share and an equal number of Warrants with an exercise price of $0.013 for total consideration to the Company of $800,000. On August 12, 2022 and November 9, 2022, the number shares was increased to 153,846,154 (for total consideration to the Company of $1,000,000) and 200,000,000 shares (for total consideration to the Company of $1,300,000) an equal number of Warrants with an exercise price of $0.013, respectively.

 

As of December 31, 2023, and 2022, there were 3,105,704,056 and 2,693,190,084 shares of Common Stock issued and outstanding, respectively.

 

Shares to be Issued

 

During the year ended December 31, 2022, in connection with the mentioned private placements offering in August and November 2022, the Company received $576,000 in cash proceeds. During February 2023, the Company issued restricted common shares and warrants pursuant to the closing of the August 2022 Offering totaling 89,230,769 million restricted common shares and 190,323,692 million warrants. The Shares will be restricted securities and subject to required holding periods under Rule 144.

 

During the year ended December 31, 2023, the Company received $401,000 in cash proceeds.

 

 

Stock Options

 

On August 4, 2021, the Board has recognized the substantive efforts of Messrs. Leslie Bocskor, Benjamin Rote, and Dennis Forchic to sustain and support the Company over the past year without compensation while laying the foundation for the future. The Board has voted to formalize employment agreements with Messrs. Bocskor and Rote, and an advisory agreement with Mr. Forchic. Stock option agreements reflecting past contributions and incentives for the future have been issued to all three parties. Stock options plans were offered with an exercise price of $0.01 and consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic vesting immediately. On the 1-year anniversary of their respective agreements, additional stock options priced at $0.015 will vest with consideration of 150 million options to Mr. Bocskor, 100 million options to Mr. Rote, and 150 million options to Mr. Forchic.

 

In addition, the Board, consisting of Directors Rick Gutshall and Lang Coleman, having not received any consideration over the past 2 years, will receive stock options of 5 million options each at a price of $0.01 vesting immediately. The company’s legal counsel will be receiving 10 million options at a price of $0.01 vesting immediately, under the same terms as the Board, in recognition of their valuable work and support.

 

During the year ended December 31, 2022, board members Keith Crouch and Michael Blicharski were each granted the option to purchase up to 10 million shares of common stock, for a total of 20 million shares, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

During the year ended December 31, 2023, the Company granted a total of 170 million shares of stock options to the advisors as their compensation for service providing, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

Valuation

 

The Company utilizes the Black-Scholes model to value its stock options. The Company utilized the following assumptions:

 

   Year ended   Year ended 
   December 31, 2023   December 31, 2022 
Expected term   2.66 - 5.50 years    0.06-0.50 years 
Expected average volatility   180 - 203%   146%-389%
Expected dividend yield   -    - 
Risk-free interest rate   0.67 - 3.79%   0.07-0.27%

 

During the year ended December 31, 2021, the Company granted 820,000,000 options valued at $8,004,855. During the year ended December 31, 2021, the Company recognized stock option expense of $5,728,701, of which $5,631,014 was to related parties, and as of December 31, 2021, $2,276,154 remains unamortized, of which $2,276,154 is with related parties. The intrinsic value of the 820,000,000 options outstanding as of December 31, 2021 is $210,000.

 

During the year ended December 31, 2022, board members Keith Crouch and Michael Blicharski were each granted the option to purchase up to 10 million shares of common stock, for a total of 20 million shares, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

On December 20, 2022, the Company entered into a consulting agreement for general business strategy for the period of one year and a stock option agreement for compensation of services which were granted the option to purchase up to 14 million shares of common stock, at a price of $0.01 per share of common stock. Such options will vest quarterly on March 30,2023, June 30,2023 and balance on December 20,2022, with the first quarter vesting upon the grant date.

 

During the year ended December 31, 2022, the Company recognized stock option expense of $2,436,926, of which $2,420,730 was to related parties, and as of December 31, 2022, $96,777 remains unamortized, of which $48,188 is with related parties. The intrinsic value of the 854,000,000 options outstanding as of December 31, 2022, was $0

 

During the year ended December 31, 2023, the Company granted a total of 170 million shares of stock options to the advisors as their compensation for service providing, at a price of $0.01 per share of common stock. Such options will vest quarterly with the first quarter vesting upon the grant date.

 

During the year ended December 31, 2023, the Company recognized stock option expense of $440,875, of which $48,318 was to related parties, and as of December 31, 2023, $115,205 remains unamortized. The intrinsic value of the 1,024,000,000 options outstanding as of December 31, 2023, was $0

 

 

The following is a summary of stock option activity during the year ended December 31, 2023:

 

   Options Outstanding   Weighted     
   Number of   Weighted Average  

Average

Remaining life

   Fair value 
   Options   Exercise Price   (years)   on Grant Date 
                 
Outstanding, December 31, 2020   -   $-    -   $- 
Granted   820,000,000    0.012    10.00    8,004,855 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2021   820,000,000   $0.012    9.60   $8,004,855 
Granted   34,000,000    0.010    7.95    256,032 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2022   854,000,000   $0.010    8.77   $8,260,887 
Granted   170,000,000    0.012    7.09    460,820 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2023   1,024,000,000    0.012    7.09#  $8,721,707 
                     
Exercisable options, December 31, 2023   1,024,000,000   $0.012    7.09   $8,721,707 

 

Warrants

 

As part of the February 16, 2022 private placement, the Company granted warrants, which provides the option to purchase one common share for each common share purchased. The warrants issued have an exercise price of $0.01 per warrant and expire five years from the date of grant. A total of 104,600,000 warrants were granted.

 

As part of the August 12, 2022 private placement, the Company granted warrants, which provides the option to purchase one common share for each common share purchased. The warrants issued have an exercise price of $0.013 per warrant and expire five years from the date of grant. A total of 11,846,154 warrants were granted.

 

As of December 31, 2023, an investor warrant total of 644,557,692 shares of common stock was issued at an average price of $0.006 per share of common stock.

 

The following is a summary of warrant activity during the year ended December 31, 2023:

 

   Warrants Outstanding   Weighted      
   Number of   Weighted Average   Average
Remaining life
   Fair value 
   Warrants   Exercise Price   (years)   on Grant Date 
Outstanding, December 31, 2021   -   $-    -    - 
Granted   116,446,154    0.010    5.00   $726,662 
Exercised   -    -    -      
Forfeited/canceled   -    -    -      
Outstanding, December 31, 2022   116,446,154   $0.010    4.38   $726,662 
Granted   644,557,692    0.006    5.00    3,402,881 
Exercised   -    -           
Forfeited/canceled   -    -           
Outstanding, December, 2023   761,003,846   $0.007    4.19   $4,129,543 

 

The intrinsic value of the warrant outstanding as of December 31, 2023 is $0.

 

v3.24.2.u1
INCOME TAXES
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 7 - INCOME TAXES

 

Indoor Harvest operates in the United States; accordingly, federal and state income taxes have been provided based upon the tax laws and rates of the US. Deferred taxes are determined based on the temporary differences between the financial statement and income tax bases of assets and liabilities as measured by the enacted tax rates, which will be in effect when these differences reverse.

 

The components of deferred income tax assets and liabilities as of December 31, 2023 and 2022 are as follows:

 

   2023   2022 
         
Deferred tax assets          
Net operating losses  $4,096,307   $3,608,093 
Deferred tax liabilities          
Accelerated tax depreciation   -    - 
Net deferred tax assets   4,096,307    3,608,093 
           
Less: Valuation allowance   (4,096,307)   (3,608,093)
Net  $-   $- 

 

At December 31, 2023 and 2022, the Company has provided a full valuation allowance for the deferred tax assets.

 

At December 31, 2023, the Company had $19,506,224 of net operating losses (“NOLs”). NOLs generated in tax years prior to July 31, 2018, can be carryforward for twenty years, whereas NOLs generated after July 31, 2018 can be carryforward indefinitely.

 

The NOLs carry forwards are subject to certain limitations due to the change in control of the Company pursuant to Internal Revenue Code Section 382.The Company experienced a change in control for tax purposes in 2017 as a result of the merger with Alamo CBD. Accordingly, the future utilization of NOLs will be severely restricted by Section 382 of the Internal Revenue Code. Management is in the process of assessing this impact.

 

 

v3.24.2.u1
NET (LOSS) INCOME PER COMMON SHARE
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
NET (LOSS) INCOME PER COMMON SHARE

NOTE 8 - NET (LOSS) INCOME PER COMMON SHARE

 

Basic net income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods. Diluted net income per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of convertible preferred stock and convertible notes that are computed using the if-converted method, and outstanding warrants that are computed using the treasury stock method. Antidilutive stock awards consist of stock options that would have been antidilutive in the application of the treasury stock method.

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Numerator:        
Net income (loss)  $(3,261,618)  $(3,363,597)
Net income (loss) - diluted  $(3,261,618)  $(3,363,597)
           
Denominator:          
Weighted average common shares outstanding   2,913,802,800    2,695,718,387 
Effect of dilutive shares   86,862,323    - 
Diluted   3,001,440,165    2,695,718,387 
           
Net income (loss) per common share:          
Basic  $(0.00)  $(0.00)
Diluted  $(0.00)  $(0.00)

 

For the year ended December 31, 2023, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

 

v3.24.2.u1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 - SUBSEQUENT EVENTS

 

The Company evaluates subsequent events that have occurred after the balance sheet date of December 31, 2023 and up through July 16, 2024, which is the date that these financial statements are available to be issued. There are two types of subsequent events: (i) recognized, or those that provide additional evidence with respect to conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (ii) non-recognized, or those that provide evidence with respect to conditions that did not exist at the date of the balance sheet but arose subsequent to that date.

 

On February 27, 2024, the Company entered into an advisory agreement with Pacific Capital Markets LLC. Pursuant to the agreement, the company issued 100,000,000 restricted common Rule 144 shares in leiu of $100,000 cash payment for services to be rendered and performed by Pacific Capital Markets, LLC during the term of this agreement. Pacific Capital Markets, LLC is going to be advising the Company on capital formation and communications.

 

On June 19, 2024, the Company entered into an agreement with an advisor. The company agreed to issue 100,000,000 shares of common stock to the advisor and additionally pay $10,000 cash per month for one year with the ability to renew at Company’s sole and absolute discretion at the end of each year. The Advisor has had experience with certain segments of the population based on ethnicity and is advising the company on Business Development and Capital Formation in the community they have experience with.

v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Nature of Operations and Organization

Nature of Operations and Organization

 

Indoor Harvest Corp (the “Company,”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739. On August 3, 2017, we formed Alamo Acquisition, LLC, a wholly owned Texas limited liability company (“Alamo Acquisition Sub”). On August 4, 2017, we consummated a business acquisition (the “Alamo Acquisition”) pursuant to which Alamo Acquisition Sub acquired all of the outstanding member interests of Alamo CBD, LLC. (“Alamo CBD”), a Texas limited Liability Company. Upon closing of the Alamo Acquisition, the member interests of Alamo CBD were exchanged for 7,584,008 shares of Indoor Harvest’s common stock, the parent company of Alamo Acquisition Sub, and Alamo CBD continued as our surviving wholly-owned subsidiary, and Alamo Acquisition Sub ceased to exist. Pursuant to ASC 805 “Business Combinations,” the Company determined the Alamo Acquisition was an asset purchase.

 

From inception until August 4, 2017, the Company provided full service, state of the art design-build, engineering, procurement and construction services to the indoor and vertical farming industry. The Company provided production platforms, mechanical systems and complete custom designed build outs for both Controlled Environment Agriculture (“CEA”) and Building Integrated Agriculture (“BIA”), for two unique industries, produce and cannabis. In mid-2016, the Company began efforts to separate its produce and cannabis related operations due to ongoing feedback from both clients and potential institutional investors. It was determined that the Company’s involvement in the cannabis industry was creating conflicts for clients and potential institutional investors wishing to work with the Company from the produce industry due to the public perception and political issues surrounding the cannabis industry. By late-2016, the Company had decided to cease actively selling its products and services to the vertical farming industry and to focus on utilizing the Company’s developed technology and methods for the cannabis industry. On August 4, 2017, the Company ceased actively supporting business development of vertical farms for produce production.

 

On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis.

 

Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

It is management’s opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.

 

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant estimates include, but are not limited to, the estimate of percentage of completion on construction contracts in progress at each reporting period which we rely on as a primary basis of revenue recognition, estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities.

 

Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of Indoor Harvest Corp. and its wholly-owned subsidiaries, Alamo CBD and IHC. All significant inter-company accounts and transactions have been eliminated in consolidation.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with a maturity of three months or less to be cash and cash equivalents.

 

Stock Based Compensation

Stock Based Compensation

 

The Company recognizes stock-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 focuses on transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus in which an entity obtains employee services in stock-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions).

 

(Loss) Income per Share

(Loss) Income per Share

 

Basic income (loss) per share amounts are calculated based on the weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is based on the weighted average numbers of shares of common stock outstanding for the periods, including dilutive effects of stock options, warrants granted and convertible preferred stock. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported.

 

For the years ended December 31, 2023 and 2022, respectively, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
   (shares)   (shares) 
         
Series A Preferred Stock   -    - 
Convertible notes   140,283,203    - 
Warrant   761,003,846    116,446,154 
Stock option   1,024,000,000    854,000,000 
Anti dilutive Securities   1,925,287,049    970,446,154 

 

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

 

The following table summarizes fair value measurements by level at December 31, 2023 and 2022, measured at fair value on a recurring basis:

 

December 31, 2023  Level 1   Level 2   Level 3   Total 
Assets                    
None  $-   $-   $-   $- 
                     
Liabilities                    
Convertible notes, net  $-   $-   $471,904    $471,904 

 

December 31, 2022  Level 1   Level 2   Level 3   Total 
Assets                    
Notes receivable, net  $-   $-   $163,588   $163,588 
                     
Liabilities                    
None  $-   $-   $-   $- 

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes pursuant to ASC 740—Income Taxes, which requires recognition of deferred income tax liabilities and assets for the expected future tax consequences of events that have been recognized in the financial statements or tax returns. The Company provides for deferred taxes on temporary differences between the financial statements and tax basis of assets using the enacted tax rates that are expected to apply to taxable income when the temporary differences are expected to reverse.

 

ASC 740 establishes a more-likely-than-not threshold for recognizing the benefits of tax return positions in the financial statements. Also, the statement implements a process for measuring those tax positions that meet the recognition threshold of being ultimately sustained upon examination by the taxing authorities. There are no uncertain tax positions taken by the Company on its tax returns. The Company files tax returns in the U.S. and states in which it has operations and is subject to taxation. Tax years subsequent to 2011 remain open to examination by U.S. federal and state tax jurisdictions.

 

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Reform Act”). We recognize the impact of tax legislation in the period in which the law is enacted. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Tax Reform Act. Consistent with that guidance, we recognized provisional amounts based upon our interpretation of the tax laws and estimates which require significant judgments. The actual impact of these tax laws may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in our interpretations and assumptions, additional guidance that may be issued by the government and actions we may take as a result of these enacted tax laws. Any adjustments recorded to the provisional amounts will be included in income from operations as an adjustment to tax expense.

 

 

Derivative Liability

Derivative Liability

 

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2023 and 2022, the Company did not have any derivative instruments that were designated as hedges.

 

Adoption of New Accounting Standards

Adoption of New Accounting Standards

 

Effective January 1, 2019, we adopted Accounting Standards Codification 842, Leases (“ASC 842”). Operating lease right-of-use (“ROU”) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on our consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The adoption of this standard did not have a significant impact on the financial statements.

 

Recent Issued Accounting Pronouncements

Recent Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted.

v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SCHEDULE OF ANTI DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

For the years ended December 31, 2023 and 2022, respectively, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
   (shares)   (shares) 
         
Series A Preferred Stock   -    - 
Convertible notes   140,283,203    - 
Warrant   761,003,846    116,446,154 
Stock option   1,024,000,000    854,000,000 
Anti dilutive Securities   1,925,287,049    970,446,154 
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

The following table summarizes fair value measurements by level at December 31, 2023 and 2022, measured at fair value on a recurring basis:

 

December 31, 2023  Level 1   Level 2   Level 3   Total 
Assets                    
None  $-   $-   $-   $- 
                     
Liabilities                    
Convertible notes, net  $-   $-   $471,904    $471,904 

 

December 31, 2022  Level 1   Level 2   Level 3   Total 
Assets                    
Notes receivable, net  $-   $-   $163,588   $163,588 
                     
Liabilities                    
None  $-   $-   $-   $- 
v3.24.2.u1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at December 31, 2023 and 2022 are as follows:

 

   December 31, 2023   December 31, 2022 
Accounts payable  $(569,844)  $(139,603)
Credit card   (6,800)   (7,877)
Accrued expenses   (213,377)   (85,898)
Accrued management fee   (29,167)   0 
Accrued interest   (36,803)   0 
Total accounts payable and accrued liabilities  $(855,991)  $(233,378)
v3.24.2.u1
STOCKHOLDERS’ EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
SCHEDULE OF STOCK OPTIONS ASSUMPTIONS

The Company utilizes the Black-Scholes model to value its stock options. The Company utilized the following assumptions:

 

   Year ended   Year ended 
   December 31, 2023   December 31, 2022 
Expected term   2.66 - 5.50 years    0.06-0.50 years 
Expected average volatility   180 - 203%   146%-389%
Expected dividend yield   -    - 
Risk-free interest rate   0.67 - 3.79%   0.07-0.27%
SCHEDULE OF STOCK OPTION

The following is a summary of stock option activity during the year ended December 31, 2023:

 

   Options Outstanding   Weighted     
   Number of   Weighted Average  

Average

Remaining life

   Fair value 
   Options   Exercise Price   (years)   on Grant Date 
                 
Outstanding, December 31, 2020   -   $-    -   $- 
Granted   820,000,000    0.012    10.00    8,004,855 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2021   820,000,000   $0.012    9.60   $8,004,855 
Granted   34,000,000    0.010    7.95    256,032 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2022   854,000,000   $0.010    8.77   $8,260,887 
Granted   170,000,000    0.012    7.09    460,820 
Exercised   -    -    -    - 
Forfeited/canceled   -    -    -    - 
Outstanding, December 31, 2023   1,024,000,000    0.012    7.09#  $8,721,707 
                     
Exercisable options, December 31, 2023   1,024,000,000   $0.012    7.09   $8,721,707 
SCHEDULE OF WARRANTS ACTIVITY

The following is a summary of warrant activity during the year ended December 31, 2023:

 

   Warrants Outstanding   Weighted      
   Number of   Weighted Average   Average
Remaining life
   Fair value 
   Warrants   Exercise Price   (years)   on Grant Date 
Outstanding, December 31, 2021   -   $-    -    - 
Granted   116,446,154    0.010    5.00   $726,662 
Exercised   -    -    -      
Forfeited/canceled   -    -    -      
Outstanding, December 31, 2022   116,446,154   $0.010    4.38   $726,662 
Granted   644,557,692    0.006    5.00    3,402,881 
Exercised   -    -           
Forfeited/canceled   -    -           
Outstanding, December, 2023   761,003,846   $0.007    4.19   $4,129,543 
v3.24.2.u1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
SCHEDULE FOR COMPONENTS OF DEFERRED INCOME TAX ASSETS AND LIABILITIES

The components of deferred income tax assets and liabilities as of December 31, 2023 and 2022 are as follows:

 

   2023   2022 
         
Deferred tax assets          
Net operating losses  $4,096,307   $3,608,093 
Deferred tax liabilities          
Accelerated tax depreciation   -    - 
Net deferred tax assets   4,096,307    3,608,093 
           
Less: Valuation allowance   (4,096,307)   (3,608,093)
Net  $-   $- 
v3.24.2.u1
NET (LOSS) INCOME PER COMMON SHARE (Tables)
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Numerator:        
Net income (loss)  $(3,261,618)  $(3,363,597)
Net income (loss) - diluted  $(3,261,618)  $(3,363,597)
           
Denominator:          
Weighted average common shares outstanding   2,913,802,800    2,695,718,387 
Effect of dilutive shares   86,862,323    - 
Diluted   3,001,440,165    2,695,718,387 
           
Net income (loss) per common share:          
Basic  $(0.00)  $(0.00)
Diluted  $(0.00)  $(0.00)
v3.24.2.u1
SCHEDULE OF ANTI DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti dilutive Securities 1,925,287,049 970,446,154
Series A Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti dilutive Securities
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti dilutive Securities 140,283,203
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti dilutive Securities 761,003,846 116,446,154
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti dilutive Securities 1,024,000,000 854,000,000
v3.24.2.u1
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Assets    
Notes receivable, net $ 163,588
Liabilities    
Convertible notes, net 471,904
Fair Value, Inputs, Level 1 [Member]    
Assets    
Notes receivable, net
Liabilities    
Convertible notes, net
Fair Value, Inputs, Level 2 [Member]    
Assets    
Notes receivable, net
Liabilities    
Convertible notes, net
Fair Value, Inputs, Level 3 [Member]    
Assets    
Notes receivable, net 163,588
Liabilities    
Convertible notes, net $ 471,904
v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares
Aug. 04, 2017
Dec. 31, 2023
Lease term   12 months
Alamo CBD LLC [Member] | Common Stock [Member]    
Number of shares exchanged for acquisition 7,584,008  
v3.24.2.u1
GOING CONCERN (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net cash used in operations $ (518,941) $ (870,403)
Accumulated deficit $ (30,320,649) $ (27,059,031)
v3.24.2.u1
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accounts payable $ (569,844) $ (139,603)
Credit card (6,800) (7,877)
Accrued expenses (213,377) (85,898)
Accrued management fee (29,167) 0
Accrued interest (36,803) 0
Total accounts payable and accrued liabilities $ (855,991) $ (233,378)
v3.24.2.u1
CONVERTIBLE NOTES (Details Narrative) - USD ($)
12 Months Ended
Apr. 12, 2023
Dec. 31, 2023
Dec. 31, 2022
Aug. 12, 2022
Feb. 16, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Common stock share issued   3,105,704,056 2,693,190,084    
Warrants issued to purchase of common stock       $ 0.013 $ 0.01
Attorney and broker fees $ 180,500        
Conversion price per share $ 0.001        
Convertible notes payable and debt discount   $ 312,500      
Unamortized debt discount   0      
Amortization of debt discount   312,500      
Additional principal   158,594      
Outstanding principal   471,094    
Accrued interest   $ 36,803 $ (0)    
Warrant [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Warrants issued to purchase of common stock 31,250,000        
Warrants issued to purchase of common stock $ 0.01        
Common Stock [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Stock issued for default interest   109,033,203      
Board of Directors [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Convertible note issued $ 312,500        
Convertible note, discount rate 20.00%        
Convertible note interest rate 6.00%        
Interest accruing rate percentage 15.00%        
Common stock share issued 31,250,000        
v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Deposit on acquisition $ 624,289
Professional fees 1,566,940 $ 1,567,352
Electrum Partners LLC [Member]    
Deposit on acquisition 145,000  
Hemp 369 [Member]    
Deposit on acquisition 429,289  
Meta Bio Genix [Member]    
Deposit on acquisition $ 50,000  
v3.24.2.u1
SCHEDULE OF STOCK OPTIONS ASSUMPTIONS (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Expected average volatility minimum 180.00% 146.00%
Expected average volatility maximum 203.00% 389.00%
Expected dividend yield
Risk-free interest rate minimum 0.67% 0.07%
Risk-free interest rate maximum 3.79% 0.27%
Minimum [Member]    
Expected term 2 years 7 months 28 days 21 days
Maximum [Member]    
Expected term 5 years 6 months 6 months
v3.24.2.u1
SCHEDULE OF STOCK OPTION (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]        
Number of Options, Outstanding, Beginning 854,000,000 820,000,000  
Weighted average exercise price per share, Outstanding, Beginning $ 0.010 $ 0.012  
Weighted average remaining term in years, Outstanding 7 years 1 month 2 days 8 years 9 months 7 days 9 years 7 months 6 days 0 years
Fair value on grant date, Outstanding Beginning $ 8,260,887 $ 8,004,855  
Number of Options, Granted 170,000,000 34,000,000 820,000,000  
Weighted average exercise price per share, Granted $ 0.012 $ 0.010 $ 0.012  
Weighted average remaining term in years, Granted 7 years 1 month 2 days 7 years 11 months 12 days 10 years  
Fair value on grant date, Granted $ 460,820 $ 256,032 $ 8,004,855  
Number of Options, Exercised  
Weighted average exercise price per share, Exercised  
Number of Options, Cancelled/Expired  
Weighted average exercise price per share, Forfeited/canceled  
Number of Options, Outstanding, Ending 1,024,000,000 854,000,000 820,000,000
Weighted average exercise price per share, Outstanding, Ending $ 0.012 $ 0.010 $ 0.012
Fair value on grant date, Outstanding Ending $ 8,721,707 $ 8,260,887 $ 8,004,855
Number of Options, Exercisable 1,024,000,000      
Weighted average exercise price per share, Exercisable $ 0.012      
Weighted average remaining term in years, Exercisable 7 years 1 month 2 days      
Fair value on grant date, Exercisable Ending $ 8,721,707      
v3.24.2.u1
SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member] - USD ($)
12 Months Ended
Aug. 12, 2022
Feb. 16, 2022
Dec. 31, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Number of warrants, outstanding, beginning     116,446,154
Weighted average exercise price per share, outstanding, beginning     $ 0.010
Number of warrants, outstanding, beginning     $ 726,662
Number of options, granted 11,846,154 104,600,000 644,557,692 116,446,154
Weighted average exercise price per share, granted     $ 0.006 $ 0.010
Weighted average remaining term in years, granted     5 years 5 years
Number of Options, granted     3,402,881 726,662
Number of options, exercised    
Weighted average exercise price per share, forfeited/canceled    
Number of options, forfeited/canceled    
Weighted average exercise price per share, Forfeited/cancelled      
Weighted average remaining term in years, outstanding ending     4 years 2 months 8 days 4 years 4 months 17 days
Number of warrants, outstanding, ending     761,003,846 116,446,154
Weighted average exercise price per share, outstanding, ending     $ 0.007 $ 0.010
Number of warrants, outstanding, ending     $ 4,129,543 $ 726,662
v3.24.2.u1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Nov. 09, 2023
Dec. 20, 2022
Nov. 09, 2022
Aug. 12, 2022
Aug. 09, 2022
Aug. 01, 2022
Mar. 16, 2022
Feb. 16, 2022
Nov. 08, 2021
Oct. 01, 2021
Aug. 27, 2021
Aug. 04, 2021
Sep. 28, 2020
Feb. 28, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Apr. 12, 2023
May 12, 2022
May 11, 2020
Class of Stock [Line Items]                                          
Increased in shares authorized                                         10,015,000,000
Common stock per share                             $ 0.001 $ 0.001         $ 0.001
Common stock, shares authorized                             10,000,000,000 10,000,000,000         10,000,000,000
Restricted common shares                           89,230,769              
Common stock amended conversion price                 $ 0.0125   $ 0.40                    
Value of shares issued for consulting service                             $ 250,000 $ 5,000          
Excercise price       $ 0.013       $ 0.01                          
Common stock, shares issued                             3,105,704,056 2,693,190,084          
Common stock, shares outstanding                             3,105,704,056 2,693,190,084          
Proceed from cash received                             $ 401,000 $ 576,000          
Warrants                           $ 190,323,692              
Stock Option, Exercise Price, Increase                       $ 0.01                  
Stock options, granted                             170,000,000 34,000,000 820,000,000        
Sharebased compensation gross                                 $ 8,004,855        
Stock option plan expense                             $ 440,875 $ 2,436,926 5,728,701        
Stock option related party                             48,318 2,420,730 5,631,014        
Stock option unamortized related party                             $ 115,205 96,777 2,276,154        
Options related parties                               $ 48,188 $ 2,276,154        
Stock option intrinsic value shares                             1,024,000,000 854,000,000 820,000,000        
Stock option intrinsic value outstanding                             $ 0 $ 0 $ 210,000        
Options grants in period gross                             1,024,000,000 854,000,000 820,000,000      
Warrant term       5 years       5 years                          
Warrants and rights outstanding                             $ 0            
Consulting Services [Member]                                          
Class of Stock [Line Items]                                          
Shares issued for consulting service                             100,000,000            
Value of shares issued for consulting service                             $ 20,000            
Private Placement [Member]                                          
Class of Stock [Line Items]                                          
Common stock per share           $ 0.0065                              
Sale of common stock issued     200,000,000 153,846,154   123,076,923 150,000,000 150,000,000             172,230,769 116,446,154          
Sale of stock price per share             $ 0.006 $ 0.006             $ 0.001            
Cash received on transaction                             $ 524,769 $ 600,000          
Sale of common stock issued value     $ 1,300,000 $ 1,000,000   $ 800,000 $ 900,000 $ 900,000                          
Excercise price     $ 0.013 $ 0.013   $ 0.013                              
Private Placement [Member] | Minimum [Member]                                          
Class of Stock [Line Items]                                          
Sale of stock price per share                             $ 0.000375 $ 0.005          
Private Placement [Member] | Maximum [Member]                                          
Class of Stock [Line Items]                                          
Sale of stock price per share                             $ 0.0065 $ 0.0065          
Derivative [Member]                                          
Class of Stock [Line Items]                                          
Amount converted                                 $ 738,000        
Common Stock [Member]                                          
Class of Stock [Line Items]                                          
Value of shares issued for convertible note                             $ 312,500            
Conversion of shares                                 60,000,000        
Number of shares issued                             412,513,972 117,280,154          
Shares issued for consulting service                             100,000,000 834,000          
Value of shares issued for consulting service                             $ 100,000 $ 834          
Shares issued for convertible note                             31,250,000            
Stock issued for default interest                             109,033,203            
Warrant [Member]                                          
Class of Stock [Line Items]                                          
Excercise price                                     $ 0.01    
Warrants granted       11,846,154       104,600,000             644,557,692 116,446,154          
Warrants issued                                     31,250,000    
Accredited Investors [Member] | Common Stock [Member]                                          
Class of Stock [Line Items]                                          
Sale of common stock issued                 16,000,000                        
Sale of stock price per share                 $ 0.001                        
Cash received on transaction                 $ 200,000                        
Leslie Bocskor [Member]                                          
Class of Stock [Line Items]                                          
Stock Issued During Period, Value, New Issues                       $ 150,000,000                  
Benjamin Rote [Member]                                          
Class of Stock [Line Items]                                          
Stock Issued During Period, Value, New Issues                       100,000,000                  
Dennis Forchic [Member]                                          
Class of Stock [Line Items]                                          
Stock Issued During Period, Value, New Issues                       $ 150,000,000                  
Rick Gutshal [Member]                                          
Class of Stock [Line Items]                                          
Stock options, granted                       5,000,000                  
Shares issued price per share                       $ 0.01                  
Lang Coleman [Member]                                          
Class of Stock [Line Items]                                          
Stock options, granted                       10,000,000                  
Shares issued price per share                       $ 0.01                  
Michael Blicharski [Member]                                          
Class of Stock [Line Items]                                          
Stock options, granted                               10,000,000          
Keith Crouch and Michael Blicharski [Member]                                          
Class of Stock [Line Items]                                          
Stock options, granted                               20,000,000          
Shares issued price per share                               $ 0.01          
Advisors [Member] | Common Stock [Member]                                          
Class of Stock [Line Items]                                          
Stock options, granted                             170            
Shares issued price per share                             $ 0.01            
Subscription Agreements [Member] | Accredited Investors [Member] | Private Placement [Member]                                          
Class of Stock [Line Items]                                          
Share price                                       $ 0.005  
Consulting Agreement [Member]                                          
Class of Stock [Line Items]                                          
Common stock per share   $ 0.01                                      
Vesting description   Such options will vest quarterly on March 30,2023, June 30,2023 and balance on December 20,2022, with the first quarter vesting upon the grant date.                                      
Consulting Agreement [Member] | Maximum [Member]                                          
Class of Stock [Line Items]                                          
Options grants in period gross   14,000,000                                      
1-Year Anniversary [Member] | Leslie Bocskor [Member]                                          
Class of Stock [Line Items]                                          
Stock Issued During Period, Value, New Issues                       $ 150,000,000                  
Stock options price                       $ 0.015                  
1-Year Anniversary [Member] | Benjamin Rote [Member]                                          
Class of Stock [Line Items]                                          
Stock Issued During Period, Value, New Issues                       $ 100,000,000                  
1-Year Anniversary [Member] | Dennis Forchic [Member]                                          
Class of Stock [Line Items]                                          
Stock Issued During Period, Value, New Issues                       $ 150,000,000                  
Electrum Partners LLC [Member] | Restricted Stock [Member]                                          
Class of Stock [Line Items]                                          
Debt conversion, shares issued                         5,125,000                
Promissory Note [Member] | Electrum Partners LLC [Member]                                          
Class of Stock [Line Items]                                          
Debt conversion amount                   $ 10,000                      
10% Fixed Convertible Promissory Note [Member]                                          
Class of Stock [Line Items]                                          
Debt conversion amount $ 25,000                                        
Debt conversion, shares issued         11,388,889                                
Series A Convertible Preferred Stock [Member]                                          
Class of Stock [Line Items]                                          
Preferred stock, par value                             $ 0.01 $ 0.01         $ 0.01
Preferred stock, shares authorized                             15,000,000 15,000,000         15,000,000
Preferred stock, conversion price                 $ 0.0125                 $ 0.00006      
Deemed convertible preferred stock                                 $ 1.00        
Preferred stock, convertible, terms                                   The Series A Preferred Stock also had a “down-round” protection feature provided to the investors if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $1.00 per common share. The conversion price would be automatically adjustable down to the price of the instrument being issued. As a result of conversion during the year ended December 31, 2020, the Series A Preferred Stock conversion price was reset to $0.00006 per share.      
Common stock, conversion price                                   $ 1.00      
Preferred stock, shares issued                             0 0          
Preferred stock, shares outstanding                             0 0          
Series A Convertible Preferred Stock [Member] | Supplemental Agreement [Member]                                          
Class of Stock [Line Items]                                          
Restricted common shares                 60,000,000                        
Series A Preferred Stock [Member]                                          
Class of Stock [Line Items]                                          
Value of shares issued for convertible note                     $ 500,000                    
Conversion of shares                                 750,000        
Investor Warrant [Member]                                          
Class of Stock [Line Items]                                          
Share price                             $ 0.006            
Warrants issued                             644,557,692            
v3.24.2.u1
SCHEDULE FOR COMPONENTS OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Net operating losses $ 4,096,307 $ 3,608,093
Accelerated tax depreciation
Net deferred tax assets 4,096,307 3,608,093
Less: Valuation allowance (4,096,307) (3,608,093)
Net
v3.24.2.u1
INCOME TAXES (Details Narrative)
Dec. 31, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Accumulated net operating loss $ 19,506,224
v3.24.2.u1
SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Numerator:    
Net income (loss) $ (3,261,618) $ (3,363,597)
Net income (loss) - diluted $ (3,261,618) $ (3,363,597)
Denominator:    
Weighted average common shares outstanding 2,913,802,800 2,695,718,387
Effect of dilutive shares 86,862,323
Diluted 3,001,440,165 2,695,718,387
Net income (loss) per common share:    
Basic $ (0.00) $ (0.00)
Diluted $ (0.00) $ (0.00)
v3.24.2.u1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jun. 19, 2024
Feb. 27, 2024
Feb. 28, 2023
Dec. 31, 2023
Dec. 31, 2022
Subsequent Event [Line Items]          
Stock issued during period restricted stock     89,230,769    
Value of stock issued in lieu of cash for services, shares       $ 250,000 $ 5,000
Advisory Agreement [Member] | Subsequent Event [Member]          
Subsequent Event [Line Items]          
Stock issued during period restricted stock 100,000,000        
Value of stock issued in lieu of cash for services, shares $ 10,000        
Advisory Agreement [Member] | Pacific Capital Markets Llc [Member] | Subsequent Event [Member]          
Subsequent Event [Line Items]          
Stock issued during period restricted stock   100,000,000      
Value of stock issued in lieu of cash for services, shares   $ 100,000      

Indoor Harvest (CE) (USOTC:INQD)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Indoor Harvest (CE) Charts.
Indoor Harvest (CE) (USOTC:INQD)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Indoor Harvest (CE) Charts.